先端医療シリーズ30　神経内科の最新医療

出版社： 先端医療技術研究所
著者：
発行日： 2004-11-29
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 4925089374
電子書籍版： 2004-11-29 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

10,162 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

5,080 円(税込)

購入する

商品紹介

本書は、現時点における神経内科の領域での先端医療についてあらゆる観点から網羅したものであり、5年前の同書の最新版である。

目次

  • 先端医療シリーズ30　神経内科の最新医療

    ―目次―

    序文
    序章　神経内科の課題と展望
    第1章　神経内科のトピックス
    第2章　新しい神経治療法
    第3章　脳血管障害
    第4章　アルツハイマー病とその治療
    第5章　パーキンソン病
    第6章　運動ニューロン病の分子病態と治療
    第7章　不随意運動の病態と治療
    第8章　筋疾患とその治療
    第9章　末梢神経疾患とその治療
    第10章　神経感染症
    第11章　画像診断学の進歩
    第12章　神経疾患における新しい動態計測
    第13章　各種製品の臨床評価

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章

P.3 掲載の参考文献
1) Freimer N, Sabatti C:The human phenome project. Nat Genet 34:15-21, 2003
PubMed
2) Insel TR, Volkow ND, Landis SC, et al:Limits to growth. why neuroscience needs large-scale science. Nat Neurosci 7:426-427, 2004
PubMed
3) Roman GC, Tatemichi TK, Erkinjuntti T, et al:Vascular dementia Diagnostic criteria for research studies. Reports of the NINDS-AIREN International Workshop. Neurology 43:250-260, 19933
 
4) Erkinjunti T, Inzitari D,Pantoni L, et al:Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm 59 (suppl):23-30, 2000
 
5) Nordberg A:PET imaging of amyloid in Alzheimerls disease. Lancet Neurology 3:519-527, 2004
PubMed
6) Antiplatelet Trailistsl Collaboration:Collaborative overview of randomized trials of antiplatelet therapy 1:Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Brit Med J 308:81-106, 1994
PubMed
7) Antithrombotic Trialists' Collaboration:Collaborative meta-analysis of randolnized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 324:71-86, 2002
PubMed
8) 小林祥泰 (編):脳卒中データバンク, 中山書店, 東京, 2003
 
9) PROGRESS Cllaborative Group. Randomized trial of a perindopril-based blood-pressure lowering regimen among 6, 105individuals with previous stroke or transient ischemic attack. Lancet 358:1033-1041, 2001
PubMed
10) Inoue H:Under-use of warfarin for patients with non-valvular atrial fibrillation in Japan. Internal medicine 43:529-530, 2004
PubMed
11) Rowland LP:NINDS at 50. An Incomplete History Celebrating the Fiftieth Anniversary of the National Institute of Neurological Disorders and Stroke. Demos Medical Publishing, NY, 2003
 
12) 尾前照雄 (編著):日本における大規模臨床試験のあり方-国際共同研究 PROGRESS の経験から-, 日本医事新報社, 東京, 2003
 
13) Raftery J:NICE:faster access to modern treatments? Analysis of guidance on health technologies. Brit Med J 323:1300-1303, 2001
PubMed

第1章 神経内科のトピックス

P.10 掲載の参考文献
1) 中島 孝 (総監修):難病患者等ホームヘルパー養成研修テキスト第6版, 社会保険出版社, 東京, 2004
 
2) WHOQOL Group:Development of WHOQOL:Rational and Current Status, International Journal of Mental Health 23:24-56, 1994
 
3) Fukuhara S, et al:Psycholometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 51:1045-1053, 1998
PubMed
4) 日本語 EuroQol 開発委員会:日本語 EuroQol の開発.医療と社会 8:109-123, 1999
 
5) Greenhalgh T, Hurwitz B:Narrative based medicine, Why study narrative?BMJ 318:48-50, 1999
PubMed
6) Hickey A, O'Boyle CA, McGee HM, et al:The Schedule for the evaluation of individual quality of life, Caperer 10, Individual Quality of Life, ed Joyce CRB, O'Boyle CA, McGee HM:Harwood Academic Publishers, New York, p119-133, 1999
 
7) Neudert C, Wasner M, Borasio GD:Patients' assessment of quality of life instruments:a randomized study of SIP, SF-36 and SEIQOL-DW in patients with amyotrophic lateral sclerosis, J Neurol Sci 191:103-109, 2001
PubMed
8) 中島 孝:筋萎縮性側索硬化症患者に対する生活の質 (QoL) 向上への取り組み.神経治療学 20:139-147, 2003
 
9) 中島 孝:緩和ケアとはなにか. 難病と在宅ケア 9:7-11, 2003
 
10) 中島 孝:これからの緩和医療とは何か. 新医療 31:138-142, 2004
 
11) Palliative Care in Amyotrophic Lateral Sclerosis, Oxford University Press, Oxford, 2000
 
P.14 掲載の参考文献
1) Sasaki M, Honmou O, Akiyarma Y, et al:Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons. Glia 35:26-34, 2001
 
2) Iihoshi S, Honmou O, Houkin K, et al:Atherapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Research 1007:1-9, 2004
 
3) Akiyama Y, Radtke C, Honmou O, et al:Remyelination of the spinal cord following intravenous delivery of bone marrow cells. Glia 39:229-236, 2002
PubMed
4) 本望 修, 上出廷治, 端 和夫:神経幹細胞応用の可能性について. 脳神経外科 29:293-304, 2001
 
5) Akiyanla Y, Honmou O, Kato T, et al:Transplantation of clonal neural precursor cells derived from adult human brain establishes functional peripheral myelin in the rat spinal cord. Exp Neurol 167:27-39, 2001
 
6) Boruch AV, Conners JJ, Pipitone M, et al:Neurotrophic and migratory properties of an olfactory ensheathing cell line. Glia 33:225-229, 2001
PubMed
7) Kato T, Honmou O, Uede T, et al:Transplantation of human olfactory ensheathing cells elicits remyelination of demyelinated rat spinal cord. Glia 30:209-218, 2000
PubMed
8) Inoue M, Honmou O, Oka S, et al:Comparative analysis of remyelinating potential of focal and intravenous administra-tion of autologous bone marrow cells into the rat demyelinated spinal cord. Glia 44:111-118, 2003
 
9) Nelson PT, Kondziolka D, Wechsler L, et al:Clonal Human (hNT) Neuron Grafts for Stroke. Therapy (Nuropathology in a Patient 27 Months after Implantation) . Am J Pathol 160:1201-1206, 2002
 
10) 本望 修, 岡 真一, 佐々木祐典ほか:ヒト神経幹細胞の分離培養と脳卒中モデルでの機能回復. 脳卒中 24:355-358, 2003
 
11) Kurozumi K, Nakamura K, Tamiya T, et al:BDNF Gene-Modified Mesenchymal Stem Cells Promote Functional Recovery and Reduce Infarct Size in the Rat Middle Cerebral Artery Occlusion Model. Molecular Therapy 9:189-197, 2004
PubMed
12) Yip S, Aboody KS, Burns M, et al:Neural stem cell biology may be well suited for improving brain tumor therapies. Cancer J 9:189-204, 2003
PubMed
13) Nakamura K, Ito Y, Kawano Y, et al:Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Therapy 11:1155-1164, 2004
 
14) Olanow CW, Goetz CG, Kordower JH, et al:Adouble-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54:403-414, 2003
 
15) Li Y, Chen J, Wang L, et al:Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett 316:67-70, 2001
 
16) Honmou O, Felts PA, Waxman SG, et. al:Restoration of normal conduction properties in demyelinated spinal cord axons in the adult rat by transplantation of exogenous Schwann cells. J Neurosci 16:3199-3208, 1996
 
17) Oka S, Honmou O, Akiyama Y, Sasaki M, et al:Autologous transplantation of expanded neural precursor cells into the demyelinated monkey spinal cord. Brain Res:2004 (in press)
 
18) Cogle CR, Yachnis AT, Laywell ED, et al:Bone marrow transdifferentiation in brain after transplantation:a retrospective study. Lancet 363:1432-1437, 2004
PubMed
P.21 掲載の参考文献
1) 山口武典:脳梗塞急性期医療の実態に関する研究. 健康科学 総合研究事業平成12年度研究報告書, 2001
 
2) 小林祥泰 (主任研究者):脳卒中急性期患者データベース構築研究. 2001年度厚生科学研究報告書, p5-169, 2001
 
3) 小林祥泰:脳卒中急性期患者データベースの概要. 小林祥泰 編:脳卒中データバンク, 中山書店, 東京, p2-7, 2003
 
4) 小林祥泰:日本人における脳卒中リスク-脳卒中データバンクより-. Hypertension Frontier 7:22-31, 2004
 
5) 小林祥泰:脳卒中急性期治療へのアプローチ. 最新医学 58:811-818, 2003
Medical*Online
6) Schwamm LH:Paul Coverdell pilot prototypes-Wave I-Moving from pilot data to ongoing process. 29th International Stroke Conference, 2004
 
7) 小林祥泰:日本における Brain attack の現状と将来の予測. 臨床神経 41:1049-1051, 2001
 
8) The National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group:Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587, 1995
 
9) 小林祥泰, 寺崎修司, 橋本洋一郎ほか:超急性期入院虚血性 脳血管障害の通常治療による3ヶ月目の転帰-脳卒中急性期 患者データベースによる前向き検討-. 脳卒中 26:2004 (in press)
 
10) Schenkel J, Weimar C, Knoll T, et al:R1--systemic thrombolysis in German stroke units--the experience from the German Stroke data bank. J Neurol 250:320-324, 2003
 
P.25 掲載の参考文献
1) Westermark P, Benson MD, Buxbaum JN, et al:Amyloid fibril protein nomenclature-2002. Amyloid:Int J Exp Clin Invest 9:197-200, 2002
 
2) Janett JT, Lansbury PT:Seeding ?one-dimensinal crystallization"of amyloid:A pathologic mechanism in Alzheimer's disease and scrapie. Cell 77:1055-1058, 1993
 
3) Gustavsson A, Engstrom U, Westermark P:Normal transthyretin and synthetic trasnthyretin fragments form amyloid-like fibrils in Vitro. Biochem Biophys Res Commun 175:1159-1164, 1991
 
4) Cathcart ES, Elliott-Bryant R:Diet, amyloid enhancing factors (AEF) and amlyloidogenesis:an hypothesis. Amyloid:Int J Exp Clin Invest 6:107-113, 1999
 
5) Johan K, Westermark G, Engstrom U, et al:Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. Proc Natl Acad Sci USA 95:2558-2563, 1998
PubMed
6) Lundmark K, Westermark G T, Nystrom S, et al:Transmissibility of systelnic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA 99:6979-6984, 2002
PubMed
7) Cui D, Kawano H, Takahashi M, et al:Acceleration of murine AA amyloidosis by oral administration of amyloid fibrils extracted from different species. Pathol Int 52:40-45, 2002
PubMed
8) Kisilevsky R, Lemieux L, Boudreau L, et al:New clothes for amyloid enhancing factor (AEF):silk as AEF. Amyloid:Int J Exp Clin Invest 6:98-106, 1999
 
9) Brown P, Preece M, Brandel J-P, et al:Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 55:1075-1081, 2000
PubMed
10) Hoshi K, Yoshino H, Urata J, et al:Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts in Japan. Neurology 55:718-721, 2000
PubMed
11) 池田修一:変異型 Creutzfeldt-Jakob 病の臨床病理像, 特に狂牛病との関連で. 脳の科学 22:771-777, 2000
 
12) Prusiner SB:Prions. Proc Natl Acad Sci USA 95:13363-13383, 1998
PubMed
13) Xing Y, Nakamura A, Chiba T, et al:Transmission of mouse senile amyloidosis. Lab Invest 81:493-499, 2001
PubMed
14) Fu X, Korenaga T, Fu Li, et al:Induction of AApoAII amyloidosis by various heterogenous amyloid fibrils. FEBS Lett in press
 
15) Johnson KH, Westermark P, Sletten K, et al:Amyloid proteins and amyloidosis in domestic animals. Amyloid:Int J Exp Clin Invest 3:270-289, 1996
 
P.31 掲載の参考文献
1) Engel J Jr, Wiebe S, French J, et al:Practice parameter:temporal lobe and localized neocortical resections for epilepsy:report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 60:538-547, 2003
 
2) Wiebe S, Blume WT, Girvin JP, et al:A randomized, controlled trial of surgery for temporallobe epilepsy. N Engl J Med 345:311-318, 2001
PubMed
3) Engel J Jr:Surgery for seizures. N Engl J Med 334:647-652, 2001
 
4) Morrell F:Whisler WW, Bleck T, et al:Multiple subpial transection:a new approach to the surgical treatmenrt of focal epilepsy. J Neurosurg 70:231-239, 1989
 
5) The vagal nerve stimulation study group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology 45:224-230, 1995
 
6) 朝倉哲彦, 中村克巳, 八代一孝ほか:難治てんかんに対する 迷走神経刺激療法. てんかん研究 17 (抄):68, 1999
 
7) Benabid AL, Minotti L, Koudsie A, et al:Antiepileptic effect of high-frequency stimulation of the subthalamic nucleus (corpus Luysi)in a case of medically intractable epilepsy caused by focal dysplasia; a 30-month follow-up:technical case report. Neurosurgery 50:1385-1392, 2002
 
8) Velasco F, Velasco M, Velasco AL, et al:Electrical stimulation of the centromedian thalamic nucleus in control of seizures:long-term studies. Epilepsia 36:63-71, 1995
PubMed
9) Hodaie M, Wennberg RA, Dostrovsky JO, et al:Chronic anterior thalamus stimulation for intractable epilepsy. Epilepsia 43:603-608, 2002
PubMed
10) Chen R, Classen J, Gerloff C, et al:Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology 48:1398-1403, 1997
PubMed
11) Vonck K, Boon P, Achten E, et al:Long-term amygdalohip-pocampal stimulation for refractory temporal lobe epilepsy. Ann Neurol 52:556-565, 2002
 
12) Carroll L:Trial underway to test 'brain pacemakers' for epilepsy. Neurology Today 4(6):2004
 
13) Gale K:The nigral control of epilepsy:Basal ganglia circuitry as a substrate for seizure control, Luders HO(ed):Deep brain stimulation and epilepsy. Martin Duniz, London, p87-96, 2003
 
14) Kahana P, Ryvlin P, Hoffmann D, et al:From hypothalamic hamartoma to cortex:what can be learnt from depth recording and stimulation?Epileptic Disord 5:205-217, 2003
 
15) Tergau F, Naumann U, Paulus W, et al:Low-frequency repetitive transcranial magnetic stimulation improves intractable epilepsy. Lancet 353:2209, 1999
PubMed
16) Theodore WH, Hunter K, Chen R, et al:Transcranial magnetic stimulation for the treatment of seizures:A controlled study. Neurology 59:560-562, 2002
PubMed
17) 木下真幸子, 池田昭夫, 人見健文ほか:成人難治てんかんに対する低頻度磁気刺激の効果. 神経治療学 19(抄):286, 2002
 
18) Lesser RP, Kim SH, Beyderman L, et al:Brief bursts of pulse stimulation terminate afterdischarges caused by cortical stimulation. Neurology 53:2073-2081, 1999
PubMed
19) Yamamoto J, Ikeda A, Satow T, et al:Low frequency electric cortical stimulation has an inhibitory effect on epileptic focus in mesial temporal lobe epilepsy. Epilepsia 43:491-495, 2002
PubMed
20) Kinoshita M, Ikeda A, Matsumoto R, et al:Electric stimulation on human cortex suppresses fast cortical activity and epileptic spikes. Epilepsia 45:787-791, 2004
PubMed
21) Dudek SM, Bear MF. Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-Daspartate receptor blockade. Proc Natl Acad Sci USA 89:4363-4367, 1992
 
22) Kirkwood A, Dudek SM, Gold JT, et al:Common forms of synaptic plasticity in the hippocampus and neocortex in vitro. Science 260:1518-1521, 1993
PubMed
23) Regis J, Rey M, Bartolomei F, et al:Gamma knife surgery in mesial temporal lobe epilepsy:a prospective multiceenter study. Epilepsia 45:504-515, 2004
PubMed
24) Rogers SW, Andrews PI, Gahring LC, et al:Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 265:648-651, 1994
 
25) Takahashi Y, Mori H, Mishina M, et al:Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua Neurology 61:891-896, 2003
PubMed
26) Ikeda A, Terada K, Mikuni N, et al:Subdural recording of ictal DC shifts in neocortical seizures in human. Epilepsia 37:662-674, 1996
PubMed
27) Rockstroh B, Elbert T, Birbaumer N, et al:Cortical self-regulation in patients with epilepsies. Epilepsy Res 14:63-72, 1993
PubMed
28) Kotchoubey B, Strehl U, Uhlmann C, et al:Modification of slow cortica potentials in patients with refractory epilepsy:a controlled outcome study. Epilepsia 42:406-416, 2001
 
29) Nitsche NA, Nirsche MS, Klein CC et al:Level of action of cathodal DC polarrisation induced inhibition of the human motor cortex. Clin Neurophysiol 114:600-604, 2003
 
30) Morrel M:Antiepileptic medications for the treatment of epilepsy. Seminar in Neurol 22:247-258, 2002
 
P.38 掲載の参考文献
1) Kim K, Uchiyama M, Okawa M, et al:An epidemiological study of insomnia among the Japanese general population. Sleep 23:41-47, 2000
PubMed
2) Liu X, Uchiyama M, Kim K, et al:Sleep loss and daytime sleepiness in the general adult population of Japan:the national epidemiological survey. Psychiatry Research 93:1-11, 2000
PubMed
3) American Sleep Disorders Association:International classification of sleep disorders, revised:Diagnostic and coding manual. Rochester, Minnesota:American Sleep Disorders Association. 1997
 
4) 睡眠障害の診断治療ガイドライン研究会 (編集):睡眠障害 の対応と治療ガイドライン, じほう, 東京, 2002
 
5) 内山 真, 田ヶ谷浩邦, 亀井雄一:精神科系睡眠薬. 図解 薬の効き方・使い方, 羊土社, 東京, 2003
 
P.42 掲載の参考文献
1) Sokoloff L, Reivich M, Kennedy C, et al:The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization:theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897-916, 1977
 
2) Okazawa H, Diksic M:Image generation of serotonin synthesis rates using alpha-methyltryptophan and PET. J Comput Assist Tomogr 22:777-785, 1998
 
3) Kuhl DE, Koeppe RA, Fessler JA, et al:In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J Nucl Med 35:405-410, 1994
PubMed
4) Syrota A, Comar D, Paillotin G, et al:Muscarinic cholinergi receptor in the human heart evidenced under physiological conditions by positron emission tomography. Proc Natl Acad Sci USA 82:584-588, 1985
PubMed
5) Mamede M, Ishizu K, Ueda M, et al:Quantification of Human Nicotinic Acetylcholine Receptors with [123I]-51A SPECT. J Nucl Med 45:1458-1470, 2004
 
6) Shinotoh H, Fukushi K, Nagatsuka S, et al:Acetyl-cholinesterase imaging:its use in therapy evaluation and drug design. Curr Pharm Des 10:1505-1517, 2004
 
7) Banati RB, Myers R, Kreutzberg GW:PK('peripheral benzodiazepinei')-binding sites in the CNS indicate early and discrete brain lesions:microautoradiographic detection of[3H]PK11195 binding to activated microglia. J Neurocytol 26:77-82, 1997
 
8) Cagnin A, Brooks DJ, Kennedy AM, et al:In-vivo measurement of activated microglia in deimentia. Lancet 358 (9280):461-467, 2001
PubMed
9) Klunk WE, Engler H, Nordberg A, et al:Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319, 2004
PubMed

第2章 新しい神経治療法

P.48 掲載の参考文献
1) Brummelkamp TR, Bernards R, Agami R:A system for stable expression of short interfering RNAs in mammalian cells. Science 29:550-553, 2002
 
2) Holen T, Amarzguioui M, Wiiger MT, et al:Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res 30:1757-1766, 2002
PubMed
3) Amarzguiou M, Holen T, Babaie E, et al:Tolerance for mutations and chemical modifications in a siRNA, Nucleic Acids Res 31:589-595, 2003
 
4) Jackson AL, Bartz SR, Schelter J, et al:Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnol 21:635-637, 2003
 
5) Bridge AJ, Pebernard S, Ducraux A, et al:Induction of an interferon response by RNAi vectors in mammalian cells, Nature Genet 34:263-2642003
 
6) Sledz CA, Holko M, de Veer MJ, et al:Activation of the interferon system by short-interfering RNAs. Nature Cell Biol 5:834-839, 2003
PubMed
7) Yokota T, Sakamoto N, Enomoto N, et al:Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 4:602-608, 2003
PubMed
8) Song E, Lee SK, Dykxhoorn DM, et al:Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol 77:7174-7181, 2003
 
9) Garrus JE, von Schwedler UK, PornillosOW, et al:Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107:55-65, 2001
PubMed
10) Surabhi RM, Gaynor RB:RNA interference directed against Viral and cellular targets inhibits human immunodeficiency Vinls Type l replication. J Virol 76:12963-12973, 2002
 
11) Arteaga HJ, Hinkula J, van Dijk-Hard 1, et al:Choosing CCR5 0r Rev siRNA in HIV-1. Nat Biotechnol 21:230-231, 2003
 
12) Sorensen DR, Leirdal M, Sioud M:Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 327:761-766, 2003
PubMed
13) Yokota T, Miyagishi M, Hino T, et. al:siRNA-based inhibition of superoxide dismutase expression; potential use in familial Amyotrophic lateral sclerosis. Biochem Biophys Res Commun 314:283-291, 2004
 
14) Gonzalez-Alegre P, Miller VM, Davidson BL, et al:Toward therapy fbr DYT1 dystonia:allele-specifc silencing of mutant Torsin A. Ann Neurol 53:781-787, 2003
 
15) Miller VM, Xia H, Marrs GL, et al:Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 100:7195-7200, 2003
PubMed
16) Li Y, Yokota T, Taira K, et al:Sequence dependent and independent, discrimination siRNA-based lnhibition of Mutant, ataxin 3 Gene Expression by siRNA. Ann Neurol 56:124-129, 2004
 
17) McCaffrey AP, Meuse L, Pham TT, et al:RNA interferece in adult mice, Nature 418:38-39, 2002
 
18) Song E, Lee S-K, W.ang J, et al:RNA interference targeting Fas protects mice from fulminant hepatitis. Nature Med 9:347-351, 2003
 
19) Xia H, Mao Q, Paulson HL, et al:siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20:1006-1010, 2002
PubMed
20) Qin XF, An DS, Chen IS, et al:Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 100:183-188, 2003
 
21) Barton GM, Medzhitov R:Retroviral delivery of small interfering RNA into primary cells. Proc. Natl Acad Sci USA 99:14943-14945, 2002
PubMed
22) Hommel JD, Sears RM, Georgescu D, et al:Local gene knockdown in the brain using viral-mediated RNA interference. Nature Med 9:1539-1544, 2003
PubMed
P.52 掲載の参考文献
1) Ramon y Cajal S:Degeneration and regeneration of the nervous system (Translated by RM Day from the 1913 Spanish edition) . Oxford University Press, Oxford, 1928
 
2) Olson L:Medicine:clearing a path for nerve growth. Nature 416:589-590, 2002
PubMed
3) Okano H:Making and repairing the mammalian brain:Introduction. Semin Cell Dev Biol 14:159, 2003
PubMed
4) Okano H:Neural stem cells:progression of basic research and perspective for clinical application. Keio J Med 51:115-128, 2002
PubMed
5) Okano H:The stem cell biology of the central nervous system. J Neurosci Res 69:698-707, 2002
PubMed
6) Okano H, Imai T, Okabe M:Musashi:a translational regulator of cell fates. J Cell Sci 115:1355-1359, 2002
 
7) Sakakibara S, Imai T, Aruga J, et al:Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell. Dev Biol 176:230-242, 1996
PubMed
8) Lendahl U, Zimmerman LB, McKay RDG:CNS stem cells express a new class of intermediate filament protein. Cell 60:585-595, 1990
 
9) Roy NS, Benraiss A, Wang S, et. al:Promoter-targeted selection and isolation of neural progenitor cells from the adult human ventricular zone. J Neurosci Res 59:321-331, 2000
 
10) Roy NS, Wang S, Jiang L, et al:In vitro neurogenesis by neural progenitor cells isolated from the adult human hippocampus. Nat Med 6:271-278, 2000
 
11) Pincus DW, Keyoung H, Restelli C, et al:FGF/BDNF-responsive neuronal progenitor cells in the adult human subependyma. Annals of Neurology 43:576-585, 1998
 
12) Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al:Neurogenesis in the adult human hippocampus. Nat Med 4:1313-1317, 1998
PubMed
13) ]Bjorklund A, Lindvall O:Self-repair in the brain. Nature 405:892-895, 2000
PubMed
14) Okada S, Nakamura M, Mikami Y, et al:Blockade of interleukin-6 receptor ameliorates functional recovery in spinal cord injury. J Neurosci Res 76:265-276, 2004
PubMed
15) Bjorklund A, Lindvall O:Cell replacemerlt therapies for central nervous system disorders. Nat Neurosci 3:537-544, 2000
PubMed
16) Okano H, Yoshizaki T, Shimazaki T, et al:Isolation and transplantation of Dopaminergic Neurons and Neural Stem Cells. Parkinson&Related Disorders 9:23-28, 2002
 
17) Okano H, Ogawa Y, Nakamura M, et al:Transplantation of neural stem cells into the spinal cord after injury. . Seminar in Cell & Devlopmental Biol 14:191-198, 200
 
P.58 掲載の参考文献
1) Adams JE, Hosobuchi Y, Fields HL:Stimulation of internal capsule for relief of chronic pain J Neurosurg 41:740-744, 1974
PubMed
2) Adams JE:Naloxone reversal of analgesia produced by brain stimulation in the human. Pain 2:161-166, 1976
PubMed
3) Hosobuchi Y, Adanis J, Bloom F, et al:Stimulation of human periaqueductal gray for pain relief increases immunoreactive beta endorphin in ventricular fluid. Science 203:279-281, 1979
 
4) Tasker RR, Organ LW, Hawrylyshyn P:The thalamus and midbrain of man. Charles C Thomas, Springfield, p275-323, 1982
 
5) Benabid AL, Pollak P, Gervason C, et al:Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 337:403-406, 1991
PubMed
6) Krack P, Pollak P, Limousin P, et al:Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease. Lancet 350:1675, 1997
PubMed
7) Lozano AM, Dostrovsky J, Chen R, et al:Deep brain stimulation for Parkinson's disease:disrupting the disruption. Lancet Neurol 1:225-231, 2002
PubMed
8) Murata J, Kitagawa M, Uesugi H, et al:Electrical stimulation of the posterior subthalamic area for the treatment of intractable proximal tremor. J Neurosurg 99:708-715, 2003
 
9) Leone M, Franzini A, Broggi G, et al:Hypothalamic deep brain stimulation for intractable chronic cluster headache:a 3-year follow-up. Neurol Sci 24(suppl 2):S143-145, 2003
 
10) Sturm V, Lenartz D, Koulousakis A, et al:The nucleus accumbens:a target for deep brain stimulation in obsessive-compulsive-and anxiety-disorders Journal of Chemical Neuroanatomy 26:293-299, 2003
PubMed
11) Kopell BH, Greenberg B, Rezai AR:Deep brain stimulation for psychiatric disorders. J Clin Neurophysiol 21:51-67, 2004
PubMed
12) Laitinen L, Bergenheim AT, Hariz MI:Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 76:53, 1992
PubMed
13) DeLong M:Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281, 1990
PubMed
14) Kleiner-Fisman G, Fisman DN, Sime E, et al:Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 99:489-495, 2003
PubMed
15) Schuurman PR, Bosch DA, Bossuyt PM, et al:Acomparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 342:461-468, 2000
 
16) Plaha P, Patel N, Gill S:Stimulation of the subthalamic region for essential tremor. J Neurosurg 101:48-54, 2004
PubMed
17) Cooper IS. Dystonia:surgical approaches to treatment and physiologic implications. In:Yahr MD, ed. The basal ganglia. New York:Raven Press, p369-383, 1976
 
18) Andrew J, Fowler CJ, Harrison MJG:Stereotaxic thalamotomy in 55 cases of dystonia. Brain 106:981-1000, 1983
 
19) Tasker RR:Surgical treatment of dystonias. in Gildenberg PL, Tasker RR eds, Textbook of Stereotactic and Functional Neurosurgery, McGraw-Hill, New York, p1015-1032, 1998
 
20) 小林智範, 平 孝臣:ジストニアに対する脳深部刺激療法. 高倉公朋, 菊池晴彦 監修:機能的脳神経外科の最先端, 先端医療技術研究所, 東京, p148-153, 2002
 
21) Cif L, El Fertit H, Vayssiere N, et al:Treatment of dystonic syndromes by chronic electrical stimulation of the internal globus pallidus. J Neurosurg Sci 47:52-55, 2003
PubMed
22) Cif L, Valente EM, Hemm S, et al:Deep brain stimulation in myoclonus-dystonia syndrome. Mov Disord 19:724-727, 2004
 
23) Taira T, Kobayashi T, Hori T:Disappearance of self-mutilating behavior in a patient with Lesch-Nyhan syndrome after bilateral chronic stimulation of the globus pallidus internus. J Neurosurg 98:414-416, 2003
 
24) Umemura A, Jaggi JL, Dolinskas CA, et al:Pallidal deep brain stimulation for longstanding severe generalized dystonia in Hallervorden-Spatz syndrome. Case report. J Neurosurg 100:706-709, 2004
PubMed
25) Kiss ZH, Doig K, Ehasziw M, et al:The Canadian multicenter trial of pallidal deep brain stimulation for cervical dystonia:preliminary results in three patients. Neurosurg Focus 17:E5, 2004
 
26) 平 孝臣, 堀 智勝:難治性疼痛に対する脳深部刺激療法. 脳と神経:2004(in press)
 
27) Temel Y, Visser-Vandewalle V:Surgery in Tourette Syndrome Movement, Disorders 91:3-14, 2004
 
P.62 掲載の参考文献
1) Barker AT, et al:Clinical evaluation of conduction time measurement in central motor pathways using magnetic stimulation of human brain. Lancet 1:1325-1326, 1986
PubMed
2) Maeda F, et al:Interindividual variability of the modulatory effects of repetitive transcranial magnetic stimulation on cortical excitability. Exp Brain Res 133:425-430, 2000
PubMed
3) Touge T, et al:Are the after-effects of low-frequency rTMS on motor cortex excitability due to changes in the efficacy of cortical synapses?Clin Neurophysiol 112:2138, 2001
PubMed
4) Wassermann EM:Risk and safety of repetitive transcranial magnetic stimulation:report and recommendations from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation June 5-7, 1996. Electroencephalogr Clin Neurophysiol 108:1-16, 1998
PubMed
5) Pascual-Leone A, et al:Akinesia in Parkinson's disease. II. Shortening of choice reaction time and movement time with subthreshold repetitive transcranial motor cortex stimulation. Neurology 44:892-898, 1994
PubMed
6) Shimamoto H, et al:Therapeutic Effect of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease. 臨 床神経学 39:1264-1267, 1999
 
7) Okabe S, et al:0.2Hz repetitive transcranial magnetic stimulation (rTMS) has no add-on effects as compared with a realistic sham stimulation in Parkinson disease (PD) . Mov Disord 18:382-388, 2003
 
8) Fuente-Fernandez R, et al:The placebo effect in Parkinson's disease. Trends Neurosci 25:302-306, 2002
PubMed
9) Strafella AP, et al:Transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci 21:RC157, 2001
PubMed
10) Shimizu H, et al:Therapeutic efficacy of transcranial magnetic stimulation for hereditary spinocerebellar degeneration. Tohoku J Exp Med 189:203-211, 1999
PubMed
11) Shiga Y, et al:Transcranial magnetic stimulation alleviates truncal ataxia in spinocerebellar degeneration. J Neurol Neurosurg Psychiatry 72:124-126, 2002
PubMed
12) 中村雄作ら:低頻度小脳連続磁気刺激による脊髄小脳変性症への治療. 臨床脳波 44:518-523, 2002
Medical*Online
13) Epstein CM, Rothwell JC:Therapeutic uses of rTMS. Plasticity in the Human Nervous System;Investigations with Transcranial Magnetic Stimulation, Cambridge University Press, Chapter 10:246-263, 2003
 
14) Berman RM, et al:A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry 47:332-337, 2000
PubMed
15) Rodriguez-Martin JLR, et. al:Transcranial magnetic stimulation for treating depression. The Cochrane Library, Issue 4, 2002
 
16) Tergau F, et al:Low-frequency repetitive transcranial magnetic stimulation improves intractable epilepsy. Lancet 353:2209, 1999
PubMed
17) Akaniatsu N, et al:Decreased susceptibility to pentylenetetrazol-induced seizures after low-frequency transcranial magnetic stimulationkmrats. Neurosci Lett 310:153-156, 2001
 
18) Siebner HR, et al:Low-frequency repetitive transcranial magnetic stimulation of the motor cortex in writer's cramp. Neurology 52:529-537, 1999
PubMed
19) 島本宝哲ら:痙性斜頚に対する経頭蓋磁気刺激の治療効果-3症例報告-. 機能的脳神経外科 40:72-73, 2001
 
P.68 掲載の参考文献
1) Leksell L:Stereotactic radiosurgery in trigeminal neuralgia. Acta Chir Scand 137:311-314, 1971
PubMed
2) Rand RW, Jacques DB, Melby RW et al:Leksell Gamma Knife treatment of tic douloureux. Stereotact. Funct. Neurosurgery 61(suppl 1):93-102, 1993
 
3) 小林達也, 田中孝幸, 木田義久ほか:三叉神経痛に対するガンマナイフ治療の早期効果. 定位的放射線治療:23-27, 1998
 
4) Kondziolka D, Lunsford LD, Flickinger JC et al:Stereotactic radiosurgery for trigeminal neuralgia;A multiinstitutional study using gamma unit. J Neurosurg 84:940-945, 1996
PubMed
5) Kondziolka D, Lunsford LD, Flickinger JC:Stereotactic radiosurgery for the treatment of trigeminal neuralgia. Clin J Pain 18:42-47, 2002
PubMed
6) Maesawa S, Salame C, Flickinger JC, et al:Clinical outcome after stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurgery 94:21-26, 2001
 
7) Regis J, Baltolomei F, Metellus P, et. al:Radiosurgery for trigeminal neuralgia and epilepsy. Neurosurg. Clin. North Am 10:359-377, 1999
 
8) Urgosik D, Vymazal J, Vladyka V, et al:Gamma knife treatment of trigeminal neuralgia; clinical and electrophysiological study. Stereotact. Funct. Neurosurg 70 (suppl 1):200-209, 1998
 
9) Young JN, Vermulen SS, Posewitz A:Gamma knife radiosurgery for the treatment of trigeminal nuralgia. Stereotact. Funct. Neurosurgery 70 (suppl 1):192-199, 1998
 
10) Lindquist L, Kihlstrom L, Hellstrand E:Functional neurosurgery-A future for the Gamma knife?Stereotact. Funct. Neurosurg 57:72-81, 1991
 
11) Nicol B, Regine WF, Courtney C, Meigooni A, Sanders M, Young B.:Gamma knife radiosurgery using 90 Gy for trigeminal neuralgia. J Neurosurg 93(suppl 3):152-154, 2000
 
12) Hasegawa T, Kondziolka D, Spiro R, et al:Repeat radiosurgery for refractory trigeminal neuralgia. Neurosurgery 50:494-500, discussion 500-502, 2002
 
13) Pollock BE, Foote RL, Stafford SL, et al:Results of repeated gamma knife radiosurgery for medically unresponsive trigeminal neuralgia. J Neurosurg 93(suppl 3):162-164, 2000
 

第3章 脳血管障害

P.72 掲載の参考文献
1) PROGRESS Collaborative Group:Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack) Lancet 358:1033-1041, 2001
PubMed
2) Chobanian AV, Bakris GL, Black HR, et al:Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee:Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252, 2003
PubMed
3) Hasegawa Y, Yamaguchi T, Omae T, et al:PROGRESS CT Substudy Investigators:Effects of perindopril-based blood pressure lowering and of patient characteristics on the progression of silent brain infarct:the Perindopril Protection against Recurrent Stroke Study(PROGRESS)CT Substudy in Japan. Hypertens Res 27:147-156, 2004
PubMed
4) Sacco RL, Benson RT, Kargman DE, et al.:High-density lipoprotein cholesterol and ischemic stroke in the elderly:the Northern Manhattan Stroke Study. JAMA 285:2729-2735, 2001
PubMed
5) Heart Protection Study Collaborative Group:Effects of cholesterol lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high risk conditions. Lancet 363:757-767, 2004
PubMed
6) Amarenco P, Bogousslavsky J, Callahan AS, et al:SPARCL Investigators:Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Gerebrovasc Dis 16:389-395, 2003
PubMed
7) Homma S, Sacco RL, Di Tullio MR, et al:PFO in Cryptogenic Stroke Study (PICSS) Investigators:Effect of medical treatment in stroke patients with patent foramen ovale:patent foramen ovale in Cryptogenic Stroke Study. Circulation 105:2625-2631, 2002
PubMed
8) Yamaguchi T, for Japanese Nonvalvular Atrial Fibrillation Study Group:Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation:a multicenter, prospective randomized trial. Stroke 31:817-821, 2000
 
9) Yasaka M, Minematsu K, Yamaguchi T:Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 40:1183-1188, 2001
PubMed
10) Warach S, Pettigrew LC, Dashe JF, et al:Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol 48:713-722, 2000
PubMed
11) Alexandrov AV, Demchuk AM, Burgin WS, et al:CLOTBUST Investigators:Ultrasound-enhanced thrombolysis for acute ischemic stroke:phase I. Findings of the CLOTBUST trial. J Neuroimaging 14:113-117, 2004
 
12) 峰松一夫, 山口武典, 端 和夫ほか:J-ACT (Japan Alteplase Clinical Trial) グループ:発症3時間以内の虚血性 脳血菅障害に対する GMK-527 (アルテプラーゼ) 静注療法 臨床試験の結果. 脳卒中 26:139, 2004
 
13) The Abciximab in Ischemic Stroke Investigators:Abciximab in acute ischemic stroke:a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 31:601-609, 2000
PubMed
14) The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators:Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke:a randomized controlled trial. JAMA 279:1265-1272, 1998
PubMed
15) Olsson SB; Executive Steering Committee on behalf of the SPORTIF III Investigators:Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III):randomised controlled trial Lancet 362:1691-1698, 2003
 
16) Halperin JL; Executive Steering Committee, SPORTIF III and V Study Investigators:Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation:Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 146:431-438, 2003
 
17) Edaravone Acute Infarction Study Group:Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15:222-229, 2003
 
18) Molyneux A, Kerr R, Stratton I, et al:International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group:International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical dipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms:a randomised trial. Lancet 360:1267-1274, 2002
 
19) International Study of Unruptured Intracranial Aneurysms Investigators:Unruptured intracranial aneurysms:risk of rupture and risks of surgical intervention. N Engl J Med 339:1725-1733, 1998
 
20) Wiebers DO, Whisnant JP, Huston J 3rd, et. al:International Study of Unruptured Intracranial Aneurysms Investigators:International Study of Unruptured Intracranial Aneurysms Investigators. Unruptured intracranial aneurysms:natural history, clinical outcome, and risk of surgical and endovascular treatment. Lancet 362:103-110, 200, 3
 
21) The EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med 313:1191-1200, 1985
 
P.78 掲載の参考文献
1) 大友英一, 荒木五郎, 伊藤栄一ほか:脳血栓症におけるウロキナーゼの臨床的有用性について-Placeboを対照とした多施設群間二重盲検による試験-. 臨評価 13:711-751, 1985
 
2) Wardlow JM, del Zoppo, Yamaguchi T, et al:Thrombolysis for acute ischaemic stroke. In The Cochrane Library Issue 4, Update Software, Oxford, 2002
 
3) Multicenter Acute Stroke Trial-Italy Group:Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 346:1509-1514, 1995
PubMed
4) Multicenter Acute Stroke Trial-Europe Study Group:Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 335:145-150, 1996
 
5) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group:Tissue plaminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587, 1995
 
6) Adams Jr HP, Adams RJ, Brott T, et al:Guidelines for the early management of patients with ischemic stroke. A scientific statement from the stroke council of the American Stroke Association. Stroke 34:1056-1083, 2003
 
7) Hacke W, Kaste M, Fiechi C, et al:Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke, the European Cooperative Acute Stroke Study (ECASS). JAMA 274:1017-1025, 1995
 
8) Hacke W, Kaste M, Fiechi C, et al:Randamized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS H). Lancet 352:1245-1251, 1998
 
9) Clark WM, Wissmn S, Albers GW, et al:Recombinant tissue type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study:a randomized controlled trial. JAMA 282:2019-2026, 1999
 
10) Graham GD:Tissue plaminogen activator for acute ischemic stroke in clinical practice:a meta-analysis of safety data. Stroke 34:2847-2850, 2003
 
11) Katzan IL, Hammer MD, Hixson ED, et al:Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 61:346-350, 2004
PubMed
12) Schellinger PD, Kaste M, Hacke W:An update on thrombolytic therapy for acute stroke. Current Opinion in Neurology 17:69-77, 2004
PubMed
13) 健康科学総合研究事業. 脳梗塞急性期の実態に関する研究 (H10-健康-071). 平成12年度研究報告
 
14) Yamaguchi K, Hori S, Nogawa S, et al:Thrombolysis candidates for the treatment of stroke at an emergency department in Japan. Acad Emerg Med 9:754-758, 2002
PubMed
15) 峰松一夫, 山口武典, 端 和夫ほか:発症3時間以内の虚血性脳血管障害に対する GMK-527 (アルテプラーゼ) 静注療法臨床試験の結果. 脳卒中 26:139(抄録), 2004
 
16) Furlan A, et al:Intra-arterial prourokniase for acute ischemic stroke. The PROACT II Study:A randomized controlled Trial. JAMA 282:2003-2011, 1999
PubMed
17) Lawandowski CA, Frankel M, Tomsick TA, et al:Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke:Emergency Management of Stroke (EMS) Bridging Trial Stroke 30:2598-2605, 1999
 
18) Donnan GA, et al:Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy. Lancet Neurology 1:417-425, 2002
PubMed
19) 脳卒中合同ガイドライン委員会:脳卒叩治療ガイドライン 2004. 協和企両, 東京, 2004
 
P.85 掲載の参考文献
1) 内山真一郎, 山崎昌子, 丸山勝一:クロピドグレルの抗血小板作用. 特集:血小板機能. 日本臨牀 50:372-278, 1994
 
2) Jarvis B, Simpson K:Clopidogrel. A review of its use in the prevention of arherothrombosis. Drugs 60:347-377, 2000
PubMed
3) 池田康夫, 内山真一郎, 山口武典ほか:硫酸クロピドグレルの血小板凝集抑制作用-用量比較臨床薬理試験-. 脳卒中 24:381-392, 2000
 
4) Hollopeter G, Jantzen HM, Vincent D, et al:Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202-207, 2001
PubMed
5) CAPRIE Steering Committee:A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) . Lancet 348:1329-1339, 1996
 
6) Antithrombotic Trialists Collaboration:Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324:71-86, 2002
 
7) Hankey GJ, Sudlow CLM, Danbabin DW, et al:Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 31:1779-1784, 2000
PubMed
8) Uchiyama S, Yamazaki M, Maruyama S, et al:Shear-induced platelet aggregation in cerebral ischemia. Stroke 25:1547-1551, 1994
PubMed
9) 内川真一郎:ずり応力惹起血小板凝集と脳虚血. 日本バイオレオロジー学会誌 11:76-85, 1997
 
10) Uchiyama S, Nagayama T, Sone R, et al:Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia. Stroke 20:1643-1647, 1989
PubMed
11) Yamazaki M, Uchiyama S, Iwata M, et al:Measurement of platelet fibrinogen binding and P-selectin expression in patients with ischemic cerebrovascular disease. Thromb Res 104:197-205, 2001
PubMed
12) Leon MB, Baim DS, Popma JJ, et al:A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339:1665-1671, 1998
PubMed
13) Diener H-C, Bogouslavsky J, Brass LM, et al on behalf of the MATCH Investigators:Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients(MATCH):randomized, double-blind, placebo-controlled trial. Lancet 364:331-337, 2004
PubMed
14) Umekawa H, Tanaka T, Kimura Y, et al:Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography. Biochem Phanmacol 33:3339-3344, 1984
PubMed
15) Kimura Y, Tani T, Kanbe T, et al:Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimmitte-forschung 35:1144-1149, 1985
 
16) Nomura S, Shouzu A, Omoto S, et al:Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost 80:388-392, 1998
PubMed
17) Inoue T, Sohma R, Morooka S, et al:Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro. Thromb Res 93:137-143, 1999
PubMed
18) Sorkin EM, Markham A:Cilostazol. Drugs 14:63-73, 1999
PubMed
19) Mochizuki Y, Oishi M, Mizutani T:Effects of cilostazol on cerebral blood flow, P300, and serum lipid levels in the chronic stage of cerebral infarction. J Stroke Cerebrovasc Dis 10:63-69, 2001
PubMed
20) Takahashi S, Oida K, Fujiwara R, et al:Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture, J Cardiovasc Pharmacol 20:900-906, 1992
PubMed
21) Mizutani M, Okuda Y, Yainashita K:Effect of cilostazol on the production of platelet-derived growth factor in cultured human vascular endothelial cells. Biochem Molecular Med 57:156-158, 1996
 
22) Aoki M, Morishita R, Hayashi S, et al:Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model Diabetologia 44:1034-1042, 2001
PubMed
23) Nakamura T, Houchi H, Minami A, et al:Endothelial-dependent relaxation by cilostazol, a phosphodiesterase III inhibitor, on rat thoracic aorta. Life Sci 69:1709-1715, 2001
PubMed
24) Kim KY, Shin HK, Choi JM, et al:Inhibition of lipopolysaccaride-induced apoptosis by cilostazol inhuman umbilical vein endothelial cells. J Pharmacol Exp Therap 300:709-715, 2002
 
25) Nishio Y, Kashiwagi A, Takahara N, et al:Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of moncyte chemoattractant protein-1 in response to tumor necrosis factor-a in vascular endothelial cells. Horm Metab Res 29:491-495, 1997
 
26) Otsuki M, Saito H, Xu X, et al:Cilostazol repress vascular cel adhesion molecule-1 gene transcription via inhibiting NF-κ B binding to its recognition sequence. Atherosclerosis 158:121-128, 2001
 
27) Yamazaki M, Uchiyama S, X Tsu, et al:Effects of remnant-Like particle on shear-induced platelet aqctivation and its inhibition by antiplatelet agents. Thromb Res:2004(in press)
 
28) Kimura Y, Uchiyama S, Iwata M:Effects of cilostazol on hemorheology in a microcirculation model. 5th International Stroke Congress, Vancouver, 2004
 
29) Gotoh F, Tohgi H, Hirai S, et al:Cilostazol Stroke Prevention Study. A placebo-controlled double-blind trial for secondary prevention of cerebral infarction, J Stroke Cerebrovasc Dis 9:147-157, 2000
PubMed
30) Hara H, Osakabe M, Kitajima A, et al:MCI-9092, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost 65:415-420, 1991
 
31) Hara H, Kitajima A, Shimada H, et al:Antithrombotic effects of MCI-9092, a new antiplatelet agent on experimental thrombosis models. Thromb Haemost 66:484-488, 1991
PubMed
32) 矢尾善英, 石丸 新:セロトニン拮抗薬. 特集:抗血小板薬の選択. 血栓と循環 6:102-106, 1998
 
33) De Clerck F, David JL, Janssen PAJ:Inhibition of 5-hydroxytryptamine-induced and amplified human platelet aggregation by ketanserin (R 41468), a selective 5-HT2 receptor antagonist. Agents Actions 12:388-397, 1982
 
34) Van Nueten JM, Janssen WJ, Vanhoutte PM:Serotonin and vascular smooth muscle. Vanhuette PM (ed):Serotonin and the Cardiovascular System, Raven Press, New York, p95-103, 1985
 
35) Coller BS:Anti-GP IIb/III a drugs:current strategies and future directions. Thromb Haemost 86:427-443, 2001
 
36) 内山真一郎, 山崎昌子:新しい抗血小板療法-GP IIb/ III a 阻害薬-. 杉田秀夫, 福内靖男, 柴崎 浩 (監):脳血管障 害とその治療. 神経・筋疾患の最新医療, 先端医療シリーズ 14神経・筋疾患, 先端医療技術研究所, 東京, p78-82, 2001
 
37) Coller BS:Binding of abciximab to αVβ3 and activated aMβ2 receptors:with a review of paltelet-leukocyte interactions. Thromb Haemost 82:326-336, 1999
 
38) Coller BS:Platelets and thrombolytic therapy. N Engl J Med 322:33-42, 1990
PubMed
39) Ambrose JA, Hawkey M, Badimon JJ, et al:In vivo demonstration of antithrombin effect of abciximab. Am J Cardiol 86:150-152, 2000
PubMed
40) Barry OP, Fitz Gelald GA:Mechanisms of cellular activation by platelet microparticles. Thromb Haemost 82:794-800, 1999
 
41) The Abciximab in Ischemic Stroke Investigators:Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 31:601-609, 2000
PubMed
42) Adams H, Hacke W for the AbESTT Investigators:Abciximab in emergent stroke treatment trial (AbESTT). Stroke (abstr.) 31:2864-2865, 2000
 
43) Topol EJ, Easton JD, Harrinton RA, et al:Randomized, double-blind, placebo-controlled, international trial of the oral II b/III a antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 108:16-23, 2003
 
44) 山崎昌子, 内山真一郎, 岩田 誠:血小板活性化および活性 化白血球の顆粒球への接着に及ぼすGP II b/III a 阻害薬の影響. 血栓止血誌 (抄録) 11:494, 2000
 
45) Gustafsson D, Antonsson T, Bylund R, et al:effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Hemmost 79:110-118, 1998
PubMed
46) Gustafsson D, Elg M:The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagtran and its active metabolite melagatran:a mini-review. Thromb Res 109(suppl):S9-S15, 2003
 
47) Bredherg E, Andersson TB, Frison L, et al:Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokiet 42:765-777, 2003
 
48) Executive Steering Committee on behalf of the SPORTIF III Investigators:Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III):randomized controlled trial. Lancet, 362:1691-1698, 2003
 
P.90 掲載の参考文献
1) 篠原幸人:無症候性脳血管障害:診断と対策, VI. 脳検診 (脳ドック) の意義と現状. 日内会誌 86:787-791, 1997
 
2) Shinohara Y, Takahashi W, Takagi S, et al:Present status of brain check-up system for apparently healthy people in Japan. Presented at 17th World Congress of Neurology, London, 2001
 
3) 高橋若生:脳ドックでみつかる異常-その頻度と対応-. 臨床成人病 31:1609-1616, 2001
 
4) 篠原幸人:Silent cerebrovascular disease-特にいわゆる無症候性虚血性脳血管障害について. Annual Review 神経 1996, 後藤文男ほか編:中外医学社, 東京, p98-104, 1995
 
5) Fisher CM:Lacunes-small deep cerebral infarct. Neurology 15:774-784, 1965
PubMed
6) 篠原幸人:無症候性脳梗塞は脳梗塞へ進展するか. Clin Neurosci 21:74-76, 2003
 
7) 難波昭子, 浜野 均, 北川泰久ほか:脳卒中初回発作症例における MRI上の無症候性虚血性病変-虚血性脳血管障害例 における特徴と脳卒中危険因子との関連. 脳卒中 190:389-396, 1997
 
8) Shinohara Y, Takahashi W, Takagi S, et al:Asymptomatic cerebral infarction and MRI-T2-defined cerebral ischemic lesions as predicting factor for coming symptomatic stroke. Presented at 5th World Stroke Congress, June, Vancouver, 23-26, 2004
 
9) Liebetrau M, Steen B, Hamann GF, et al:Silent and symptomatic infarcts on cranial computerized tomography in relation to dementia and mortality. A population-based study in 85-year-old subjects. Stroke 35:1816-1820, 2004
PubMed
10) Vermeer SE, Prins ND, den Heijer T, et al:Silent brain infarcts and the risk of dementia and cognitive decline. N Eng J Med 348:1215-1222, 2003.
 
11) 篠原幸人:神経治療学と Evidence-based medicine (EBM)-脳血管障害治療への応用. 神経治療学 16:41-49, 1999
 
12) Shinohara Y, and PICA Study Group:Effects of Ca antagonist on development and extension of asymptomatic as well as symptomatic cerebral infarction in hypertensives (PICA Study)-Design and results at enrollment-(to be published)
 
13) Bernick C, Kuller L, Dulberg C, et al:Silent MRI infarcts and the risk of future stroke:the Cardiovascular Health Study. Neurology 57:1222-1229, 2001
PubMed
14) PROGRESS Collaborative Group:Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet 358:1033-1041, 2001
PubMed
15) 脳卒中治療ガイドライン 2004:(第2版, 第1刷) 篠原幸人ほか編:協和企画, 東京, 2004
 

第4章 アルツハイマー病とその治療

P.97 掲載の参考文献
1) Petersen RC, Stevens JC, Ganguli M, et al:Practice parameter:early detection of dementia:mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1133-1142, 2001
 
2) Knopman DS, DeKosky ST, Cummings JL, et al:Practice parameter:diagnosis of dementia (an evidence-based review) . Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1143-1153, 2001
 
3) The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group:Consensus report of the Working Group on:? "Molecular and Biochemical Markers of Alzheimerls Disease". Neurobiol Aging 19:109-116, 1998
 
4) Kanai M, Matsubara E, Isoe K, et al:Longitudinal study of cerebrospinal fluid Ievels of tau, A β 1-40 and A β 1-42(43)in Alzheimer's disease:A study in Japan. Ann Neurol 44:17-26, 1998
 
5) Kawarabayashi T, Younkin LH, Saido TC, et al:Age-dependent changes in brain, CSF, and plasma amyloid B? protein in the Tg2576 transgenic mouse model of Alzheimerls disease. J Neurosci 21:372-381, 2001
 
6) Shoji M, Kanai M, Matsubara E, et al:Taps to Alzheimer's Patients:A continuous Japanese study of cerebrospinal fluid biomarkers. Am Neurol 48:402, 2000
 
7) Andreasen N, Minthon L, Davidsson P, et al:Evaluation of CSF-tau and CSF-A B 42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58:373-379, 2001
 
8) Shoji M, Matsubara E, Murakami T, et al:Cerebrospinal fluid tau in dementia disorders:A large scale multicenter study by a Japanese study group. Neurobiol Aging 23:363-370, 2002
 
9) Itoh N, et al:Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 50:150-156, 2001
PubMed
10) Hampel H, Buerger K, Zinkowski R, et al:Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease:acomparative cerebrospinal fluid study. Arch Gen Psychiatry 61:95-102, 2004
 
11) Schoonenboom NS, Pijnenburg YA, Mulder C, et al:Amyloid β(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62:1580-1584, 2004
 
12) Buerger K, et al:CSF tau protein phosphorylated at threonine 231correlates with cognitive decline in MCI subjects. Neurology 59:627-629, 2002
PubMed
13) Scheuner D, et al:Secreted amyloid β-protein similar to that in the senile plaques of Alzheimerls disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2:864-870, 1996
 
14) Mayeux R, et al:Plasma Aβ40 and Aβ42 and Alzheimer's disease:relation to age, mortality, and risk. Neurology 61:1185-1190, 2003
 
15) Matsubara E, et al:Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45:537-541, 1999
PubMed
P.102 掲載の参考文献
1) Hardy JA, Higgins GA:Alzheimer's disease:the amyloid cascade hypothesis. Science 256:184-185, 1992
PubMed
2) Glenner GG, Wong CW:Alzheimer's disease:initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885-890, 1984
PubMed
3) Kang J, Lemaire HG, Unterbeck A, et al:The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736, 1987
PubMed
4) Shoji M, Golde TE, Ghiso J, et al:Production of the Alzheimer amyloid b protein by normal proteolytic processing. Science 258:126-129, 2002
 
5) Iwatsubo T, Odaka A, Suzuki N, et al:Visualization of Aβ42 (43) and Aβ40 in senile plaques with end-specific Aβ monoclonals:evidence that an initially deposited species is Aβ42 (43). Neuron 13:45-53, 1994
 
6) Vassar R, Bennett BD, Babu-Khan S, et al:β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735-741, 1999
 
7) Takasugi N, Tomita T, Hayashi I, et al:The role of presenilin cofactors in the γ-secretase complex. Nature 422:438-441, 2003
 
8) St George-Hyslop PH:Molecular genetics of Alzheimer's disease. Biol Psychiatry 47:183-199, 2000
PubMed
9) Brown MS, Ye J, Rawson RB, et al:Regulated intramembrane proteolysis:a control mechanism conserved from bacteria to humans. Cell 100:391-398, 2000
PubMed
10) Petit A, Bihel F, Alves da Costa C, et al:New protease inhibitors prevent γ-secretase-mediated production of Aβ 40/42 without affecting Notch cleavage. Nat Cell Biol 3:507-511, 2001
 
11) Weggen S, Eriksen JL, Das P, et al:Asubset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity, Nature 414:212-216, 2001
 
12) Postina R, Schroeder A, Dewachter I, et al:A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease model. J Clin Invest 113:1456-1464, 2004
 
P.107 掲載の参考文献
1) Hardy J, Selkoe DJ:The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics. Science 297:353-356, 2002
PubMed
2) Schenk D, Barbour R, Dunn W, et al:Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177, 1999
 
3) Bard F, Cannon C, Barbour R, et al:Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-919, 2000
 
4) DeMattos RB, Bales KR, Cummins DJ, et al:Peripheral anti-Aβ antibody alters CNS and plasma Aβclearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855, 2001
 
5) DeMattos RB, Bales KR, Cummins DJ, et al:Brain to plasma amyloid-β efflux:a measure of brain amyloid burden in a mouse model of Alzheimer:s disease. Science 295:2264-2267, 2002
 
6) Dodart JC, Bales KR, Galmon KS, et al:Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 5:452-457, 2002
 
7) Weiner HL, Cynthia A, Lemere Ms, et al:Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48:567-579, 2000
 
8) Janus C, Pearson J, McLaurin J, et al:Aβ peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982, 2000
 
9) Morgan D, Diamond DM, Gottschall PE, et al:Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985, 2000
 
10) Hock C, Konietzko U, Papassotiropoulos A, et al:Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8:1270-1275, 2002
 
11) Hock C, Konietzko U, Streffer JR, et al:Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547-554, 2003
 
12) Matsuoka Y, Saito M, LaFrancois J, et al:Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J Neurosci 23:29-33, 2003
 
13) McLaurin J, Cecal R, Kierstead ME, et al:Therapeutically effective antibodies against amyloid-β peptide target amyloid-βresidues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8:1263-1269, 2002
 
14) Frenkel D, Katz O, Solomon B:Immunization against Alzheimer's β-amyloi plaques Via EFRH phage administration. Proc Natl Acad Sci USA 97:11455-11459, 2000
 
15) Bard F, Barbour R, Cannon C, et al:Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100:2023-2028, 2003
 
16) Monsonego A, Zota V, Karni A, et al:Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J Clin Invest 112:415-422, 2003
 
17) Orgogozo J-M, Gilman S, Dartigues J-F, et al:Subacute meningoencephalitis in a subset of patients with AD after Aβ:42 immiunization. Neurology 61:46-54, 2003
 
18) Nicoll JAR, Wilkinson D, Holmes C, et al:Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide:a case report. Nat Med 9:448-452, 2003
 
19) Hara H, Monsonego A, Yuasa K, et al:Development of a safe oral Aβ vaccine using recombinant adeno-associated Virus vector for Alzheimer's disease. J Alz Dis (in press)
 
P.113 掲載の参考文献
1) Eriksson PS, et al:Neurogenesis in the adult human hippocampus. Nat Med 4(11):1313-1317, 1998
PubMed
2) Gage F H:Neurogenesis in the adult brain. J Neurosci 22(3):612-613, 2002
 
3) Xu J, et al:Dopamine-dependent neurotoxicity of alpha-synuclein:a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8(6):600-606, 2002
PubMed
4) Carlsson A:Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm 109(5-6):777-787, 2002
 
5) Korczyn AD, Nussbaum M:Emerging therapies in the pharmacological treatment of Parkinson's disease. Drugs 62(5):775-786, 2002
PubMed
6) Jankovic J:Levodopa strengths and weaknesses. Neurology 58(4Suppl 1):S19-32, 2002
 
7) Danisi F:Parkinson's disease. Therapeutic strategies to improve patient function and quality of life. Geriatrics 57(3):46-50;quiz 52, 2002
 
8) Clarkson ED:Fetal tissue transplantation for patients with Parkinson's disease:a database of published clinical results. Drugs Aging 18(10):773-785, 2001
PubMed
9) Freeman TB, et al:Neural transplantation in Parkinson's disease. Adv Neurol 86:435-445, 2001
PubMed
10) Lindvall O, Hagell P:Cell therapy and transplantation in Parkinson's disease. Clin Chem Lab Med 39(4):356-361, 2001
PubMed
11) Subramanian T:Cell transplantation for the treatment of Parkinson's disease. Semin Neurol 21(1):103-115, 2001
PubMed
12) Borlongan CV, Sanberg PR:Neural transplantation for treatment of Parkinson's disease. Drug Discov Today 7(12):674-682, 2002
PubMed
13) Freed CR, et al:Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 (10):710-719, 2001
PubMed
14) Lindvall O:Neural transplantation in Parkinson's disease, Novartis Found Symp 231:110-123, 2000
PubMed
15) Wagers AJ, Christensen JL, Weissman IL:Cell fate determination from stem cells. Gene Ther 9(10):606-612, 2002
PubMed
16) Brannen CL, Sugaya K:In Vitro differentiation of multipotent, human neural progenitors in serum-free medium. Neuroreport 11(5):1123-1128, 2000
PubMed
17) Qu T, et al:Human neural stem cells improve cognitive function of aged brain. Neuroreport 12(6):1127-1132, 2001
PubMed
18) Pluchino S, et al:Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422 (6933):688-694, 2003
 
19) Kawasaki H, et al:Generation of doparninergic neurons and pigmented epithelia from primate ES cells by stromal cell-derived inducing activity. Proc Natl Acad Sci USA 99(3):1580-1585, 2002
PubMed
20) Sanchez-Pernaute R, et al:In vitro generation and transplantation of precursor-derived human dopamine neurons. J Neurosci Res 65 (4):284-288, 2001
PubMed
21) Storch A, et al:Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp Neurol 170(2):317-325, 2001
PubMed
22) Sawamoto K, et al:Generation of dopaminergic neurons in the adult brain from mesencephalic precursor cells labeled with a nestin-GFP transgene. J Neurosci 21(11):3895-3903, 2001
PubMed
23) Yan J, Studer L, McKay RD:Ascorbic acid increases the yield of dopaminergic neurons derived from basic fibroblast growth factor expanded mesencephalic precursors. J Neurochem 76(1):307-311, 2001
PubMed
24) Bentlage C, et al:Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host. Exp Neurol 159(1):177-190, 1999
PubMed
25) Sortwell CE, et al:Diminished survival of mesencephalic dopamine neurons grafted into aged hosts occurs during the immediate postgrafting interval. Exp Neurol 169(1):23-29, 2001
PubMed
26) Pencea V, et al:Neurogenesis in the subventricular zone and rostral migratory stream of the neonatal and adult primate forebrain. Exp Neurol 172(1):1-16, 2001
PubMed
27) Alvarez-Buylla A, Garcia-Verdugo JM:Neurogenesis in adult subventricular zone. J Neurosci 22(3):629-634, 2002
PubMed
28) Gage, FH, et al:Multipotent progenitor cells in the adult dentate gyrus. J Neurobiol 36(2):249-266, 1998
PubMed
29) Song HJ, Stevens CF, Gage FH:Neural stem cells from adult hippocampus develop essential properties of functional CNS neurons. Nat Neurosci 5(5):438-445, 2002
PubMed
30) Doetsch F, et al:Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97(6):703-716, 1999
PubMed
31) Englund U, et al:Grafted neural stem cells develop into functional pyramidal neurons and integrate into host cortical circuitry. Proc Natl Acad Sci USA 99(26):17089-17094, 2002
PubMed
32) Jiang Y, et al:Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418(6893):41-49, 2002
PubMed
33) Castro RF, et al:Failure of bone marrow cells to transdiffer-entiate into neural cells in vivo. Science 297(5585):1299, 2002
 
34) Wagers AJ, et al:Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 297(5590):2256-2259, 2002
PubMed
35) Ying QL, et al:Changing potency by spontaneous fusion. Nature 416(6880):545-548, 2002
PubMed
36) Terada N, et al:Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 416(6880):542-545, 2002
PubMed
37) Bahn S, et al:Neuronal target genes of the neuron-restrictive silencer factor in neurospheres derived from fetuses with Down's syndrome:a gene expression study. Lancet 359 (9303):310-315, 2002
PubMed

第5章 パーキンソン病

P.120 掲載の参考文献
1) Hattori N, Tanaka M, Ozawa T, et al:Immunohistochemical studies on Complex I, II, III, and IV of mitochondria in Parkinson's disease. Ann Neurol 30:563-571, 1991
PubMed
2) Yoritaka A, Hattori N, Uchida K, et al:Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc Natl Acad Sci USA 93:2696-2701, 1996
PubMed
3) Polymeropoulos MH, Lavedan C, Leroy E, et al:Mutation in the α-Synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047, 1997
 
4) Singleton AB, Farrer M, Johnston J, et al:α-Synuclein locus triplication causes Parkinson's disease. Science 302:841, 2003
 
5) Kitada T, Asakawa S, Hattori N, et al:Deletion mutation in a novel protein ?Parkinson's gene causes autosomal recessive juvenile parkinsonism (AR-JP). Nature 392:605-608, 1998
 
6) Bonifati V, Rizzu P, van Baren MJ, et al:Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256-259, 2003
 
7) Valente EM, Abou-Sleiman PM, Caputo V, et al:Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1. Science 304:1158-1160, 2004
PubMed
8) Shimura H, Hattori N, Kubo S, et al:Familial Parkinson's disease gene product, Parkin, is a ubiquitin-protein ligase. Nature Genet 25:302-305, 2000
PubMed
9) Orimo S, Ozawa E, Nakade S, et al:(123)I-metaiodobenzyl-guanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 67(2):189-194, 1999
 
10) パーキンソン病治療ガイドライン作成小委員会:パーキンソン病治療ガイドライン 2002.臨床神経 42:428-494, 2002
 
11) Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A randomized controlled trial. JAMA 284:1931-1938, 2000
 
12) Perry EK, Kilford L, Lees AJ, et al:Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 54(2):235-238, 2003
PubMed
13) The Global Parkinson's Disease Survey (GPDS) Steering Committee. Factors Impacting on Quality of Life in Parkinson's Disease. Results from an International Survey. Mov Disord 17:60-67, 2002
 
14) McKeith IG, Galasko D, Kosaka K, et al:Consortium on Dementia with Lewy Bodies. Consensus guidelines for the clinical and pathologic diagnosisof dementia with Lowy bodies (DLB):report of the consortium on DLB international workshop. Neurology 47:1113-1124, 1996
 
15) Kosaka K:Lewy bodies in cerebral cortex. Report of three cases. Acta Neuropathol(Berl)42:127-134, 1978
PubMed
P.126 掲載の参考文献
1) Howard K:First Parkinson gene therapy trial launches. Nat Biotechnol 21:1117-1118, 2003
PubMed
2) Suzuki A, Obi K, Urabe T, et al:Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral vector GCDNsap packaged in the vesicular stomatitis virus G protein. J Neurochem 82, 953-960, 2002
PubMed
3) Tanaka R, Yamashiro K, Mochizuki H, et al:Neurogenesis after transient global ischemia in the adult hippocampus visualized by improved retroviral vector. Stroke 35:1454-1459, 2004
PubMed
4) Mochizuki H, Schwartz JP, Tanaka K, et al:High-titer HIV-1-based vector systems for gene delivery into nondividing cells. J Virol 72:8873-8883, 1998
 
5) Uchida K, Takamatsu K, Kaneda N, et al:Synthesis of L-3,4-dihydroxyphenylalanine by tyrosine hydroxylase cDNA-transfected C6 cells:application for intracerebral grafting. J Neurochem 53:728-732, 1989
PubMed
6) Muramatsu S, Fujimoto K, Ikeguchi K, et al:Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13:345-354, 2002
 
7) Kordower JH, Emborg ME, Bloch J, et al:Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-773, 2000
PubMed
8) Blanchet PJ, Konitsiotis S, Mochizuki H, et al:Complications of a trophic xenotransplant approach in parkinsonian monkeys. Prog Neuropsychopharmacol Biol Psychiatry 27:607-612, 2003
PubMed
9) Vila M, Przedborski S:Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4:365-375, 2003
PubMed
10) Mochizuki H, Hayakawa H, Migita M, et al:An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 98:10918-10923, 2001
PubMed
11) Xu Harding T, Weller M, et al:Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease Proc Natl Acad Sci USA 98:10433-10438, 2001
 
12) Eberhardt O, Coelln RV, Kugler S, et al:Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 20:9126-9134, 2000
PubMed
13) Delong MR:Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285, 1990
PubMed
14) Luo J, Kaplitt MG, Fitzsimons HL, et al:Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298:425-429, 2002
 
15) Kitada T, Asakawa S, Hattori N, et al:Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608, 1998
 
16) Bonifati V, Rizzu P, van Baren MJ, et al:Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256-259, 2003
 
17) Valente EM, Abou-Sleiman PM, Caputo V, et al:Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304:1158-1160, 2004
PubMed
P.132 掲載の参考文献
1) Perlow M, Freed WJ, Hoffer B, et al:Brain grafts reduce motor abnormalities produced by destniction of nigrostriatal dopamine system. Science 204:64:3-647, 1979
 
2) Bjorklund A, Steveni U:Reconstmction of the nigro-striatal dopamine pathway by intracerebral nigral transplants. Brain Res 177:555-560, 1979
 
3) Freed CR, Greene PE, Breeze RE, et al:Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-719, 2001
PubMed
4) Olanow CW, Goetz CG, Kordower JH, et al:Adouble-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 5:403-414, 2003
 
5) Date I, Asari S, Ohmoto T:Two-year follow-up study of a patient with Parkinson's disease and severe motor fluctuations treated by co-grafts of adrenal medulla and peripheral nerve into bilateral caudate nuclei:case report. Neurosurgery 37:515-518, 1995
PubMed
6) Nakao N, Kakishita K, Uematsu Y, et al:Enhancement of the response to levodopa therapy after intrastriatal transplantation of autologous sympathetic neurons in patients with Parkinson disease. J Neurosurg 95:275-284, 2001
PubMed
7) Toledo-Aral JJ, Mendez-Ferrer S, Pardal R, et al:Trophic restoration of the nigrostriatal dopaminergic pathway in long-term carotid body-grafted parkinsonian rats. J Neurosci 23:141-148, 2003
PubMed
8) Shingo T, Date I, Yoshida H, et al:Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat. model of Parkinson's disease. J Neurosci Res 69:946-954, 2002
 
9) Svendsen CN, Caldwell MA, Shen J, et al:Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp Neurol 148:135-146, 1997
 
10) Storch A, Paul G, Csete M, et al:Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp Neurol 170:317-325, 2001
PubMed
11) Sawamoto K, Nakao N, Kakishita K, et al:Generation of dopaminergic neurons in the adult brain from mesencephalic precursor cells labeled with a nestin-GFP transgene. J Neurosci 21:3895-3903, 2001
PubMed
12) Lee SH, Lumelsky N, Studer L, et al:Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol 18:675-679, 2000
PubMed
13) Kawasaki H, Mizuseki K, Nishikawa S, et al:Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 28:31-40, 2000
PubMed
14) Barberi T, Klivenyi P, Calingasan NY, et al:Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotech 21:1200-1207, 2003
 
15) Bjorklund LM, Sanchez-Pernaute R, Chung S, et al:Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 99:2344-2349, 2002
 
16) Dezawa M, Kanno H, Hoshino M, et al:Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 112:1701-1710, 2004
 
17) Joannides A, Gaughwin P, Schwiening C, et al:Efficient generation of neural precursors from adult human skin:astrocytes promote neurogenesis from skin-derived stem cells Lancet 364:172-178, 2004
PubMed
18) Shingo T, Enwere E, Gregg C, et al:Aging results in reduced epidermal growth factor receptor signaling, diminished olfactory neurogenesis, and deficits in fine olfactory discrimination. J Neurosci 24:8354-8365, 2004
PubMed
P.137 掲載の参考文献
1) Spokes EG, Bannister R, Oppenheimer DR:Multiple system atrophy with autonomic failure:clinical, histological and neurochemical observations on four cases. J Neurol Sci 43 (1):59-82, 1979
 
2) Papp MI, Kahn JE, Lantos PL:Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) . J Neurol Sci 94(1-3):79-100, 1989
 
3) Tu PH, Galvin JE, Baba M, et al:Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neuro 44(3):415-422, 1998
 

第6章 運動ニューロン病の分子病態と治療

P.142 掲載の参考文献
1) Gurney ME, Pu H, Chiu AY, et al:Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264:1772-1775, 1994
PubMed
2) Morrison KE:Therapies in amyotrophic lateral sclerosis-beyond riluzole. Curr Opin Pharmacol 2:302-309, 2002
PubMed
3) Bruijn LI, Miller TM, Cleveland DW:Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27:723-749, 2004
PubMed
4) Nagano S, Ogawa Y, Yanagihara T, et al:Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci Lett 265:159-162, 1999
PubMed
5) Nagano S, Fujii Y, Yamamoto T, et al:The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice. Exp Neurol 179:176-180, 2003
PubMed
6) Kieran D, Kalmar B, Dick JRT, et al:Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10:402-405, 2004
PubMed
7) Azzouz M, Ralph GS, Storkebaum E, et al:VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model Nature 429:413-417, 2004
 
8) Garbuzova-Davis S, Willing AE, Milliken M, et al:Positive effect of transplantation of hNT neurons (NTera 2/D1 cell-line) in a model of familial amyotrophic lateral sclerosis. Exp Neurol 174:169-180, 2002
 
9) Miller RG, Moore DH, Gehnas DF, et al:Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 56:843-848, 2001
 
10) Cudkowicz ME, Shefner JM, Schoenfeld DA, et al:A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 61:456-464, 2003
PubMed
11) The BDNF Study group(Phase III):A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 52:1427-1433, 1999
 
12) Pattee GL, Post GR, Gerber RE et al:Reduction of oxidative stress in amyotrophic lateral sclerosis following Pramipexole treatment. Amyotroph Lateral Scler Other Motor Neuron Disord 4:90-95, 2003
PubMed
13) Groeneveld GJ, Veldink JH, van der Tweel I, et al:A randomized sequential trial of creatine in arnyotrophic lateral sclerosis. Ann Neurol 53:437-445, 2003
 
14) Kaji R, Kodama M, Imamura A, et al:Effect of ultrahigh-dose methylcobalamin on compound muscle action potential in amyotrophic lateral sclerosis:a double-blind controlled study. Muscle Nerve 21:1775-1778, 1998
PubMed
15) Mazzini L, Fagioli F, Boccaletti R, et al:Stem cell therapy in amyotrophic lateral sclerosis:a methodological approach in humans. Amyotroph Lateral Scler Other motor Neuron Disord 4:133-134, 2003
 
16) 吉野 英, 木村暁夫:筋萎縮性側索硬化症 (ALS) に対する edaravoneを用いた臨床試験. 神経治療学 20:557-564, 2003
Medical*Online
P.148 掲載の参考文献
1) Kawahara Y, Ito K, Sun H, et al:RNA editing and death of motor neurons. Nature 427:801, 2004
PubMed
2) 河原行郎, 郭 伸:AMPA 型受容体の異常～ALSをめぐる最近の動き. Brain Medical 14(1):55-62, 2002
 
3) 鈴木岳之, 都築馨介, 亀山仁彦ほか:AMPA 受容体の生理 機能-受容体機能発現から疾患まで-. 日薬理誌 122:515-526, 2003
 
4) Brusa R, Zimmermann F, Koh D, et al:Early-onset epilepsy and postnatal lethality associated with an editing-deficient Glu R-B allele in mice. Science 270:1677-1680, 1995
 
5) Carriedo SG, Yin HZ, Weiss JH:Motor neurons are selectively vulnerable to AMPA/kainite receptor-mediated injury in Vitro. JNeurosci 16:4069-4079, 1996
 
6) 郭 伸, 孫 慧, 河原行郎ほか:ALS モデル動物のAMPA受容体サブユニット分子変化と病因との関連. 厚生労働科学 研究費補助金難治性疾患克服研究事業 神経変性疾患に関する研究班 2003年度研究報告書, p43-45, 2004
 
7) Rothstein JD, Martin LJ, Kuncl RW:Decreased glutamate transporter by the brain and spinal cord in amyotrophic lateral sclerosis. N Eng J Med 326:1464-1468, 1992
 
8) Lin C-LG, Bristol LA, Dykes-Hoberg M, et al:Aberrant RNA processing in a neurodegenerative disease:the cause for absent EAAT2, aglutaniate transporter, in amyotrophic lateral sclerosis. Neuron 20:589-602, 1998
 
9) Nagai M, Abe K, Okamoto K, et al:Identification of altemative splicing forms of GLT-1 mRNA in the spinal cord of amyotrophic lateral sclerosis patients. Neurosci Lett 244:165-168, 1998
 
10) Rothstein J D, Jin L, Dykes-Hoberg M, et al:Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 90:6591-6595, 1993
 
11) Kawahara Y, Kwak S, Sun H, et al:Human spinal mononeurons express low relative abundance of GluR2 mRNA:an implication for excitotoxicity in ALS. J Neurochem 85:680-689, 2003
 
12) Takuma H, Kwak S, Yoshizawa T, et al:Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol 46:806-815, 1999
PubMed
13) Feldmeyer D, Kask K, Brusa R, et al:Neurological dysfunctions in mice expressing different levels of the Q/R site-unedited AMPAR subunit GluR-B, Nat. Neurosci 2:57-64, 1999
 
14) Kawahara Y, Kyoko Ito, Hui Sun, et al:GluR4c, an altenative splicing isoform of GluR4 is abundantly expressed in adult human brain, Mol Brain Res 127:150-155, 2004
 
15) 河原行郎, 郭 伸:ALSにおけるRNA編集異常と脊髄運動ニューロン死. 医学のあゆみ 209:979-980, 2004
Medical*Online
16) 郭 伸:ALSのグルタミン酸受容体異常と病因との関連について. 運動障害 14:33-41, 2004
Medical*Online
17) 河原行郎, 郭 伸:脳科学における RNA 編集の重要性. Clinical Neuroscience 22:250-251, 2004
 
18) Higuchi M, Maas S, Single F, et al:Point mutation in an AMPA recepotor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature 406:78-81, 2000
 
19) Hooperngardener B, Bhalla T, Staber C, et al:Nervous system targets of RNA editing identified by comparative genomics. Science 301:832-836, 2003
 
20) Wang Q, Khillan J, Gadue P, et al:Requirement of the RNA editing deaminase ADARI gene for embryonic erythropoiesis. Science 290:1765-1768, 2003
 
21) Maas S, Patt S, Schrey M, et al:Underediting of glutamate receptor Glu R-B mRNA in malignant gliomas. Proc Natl Acad Sci USA 98:14687-14692, 2001
 
22) Grigorenko EV, Bell WL, , Glazier S, et al:Editing status at the Q/R site of the GluR2 and Glu R6 glutamate receptors subunits in the surgically excised hippocampus of patients with refractory epilepsy. Neuroreport 9:2219-2224, 1998
 
23) Gurevich I, Tamir H, Arango et al:Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 34:349-356, 2002
PubMed
24) 河原行郎, 日出山拓人, 郭 伸:筋萎縮性側索硬化症の分子標的治療への展望. 最新医学 59(7):1620-1626, 2004
Medical*Online
25) Melcher T, Maas S, Herb A, et al:Amammalian RNA editing enzyme. Nature 379:460-464, 1996
 
26) Kawahara Y, Ito K, Sun H, et al:Regulation of glutamate receptor RNA editing and ADAR mRNA expression in developing human normal and Down's syndrome brains. Dev Brain Res 148:151-155, 2004
PubMed
27) Kawahara Y, Ito K, Sun H, et al:Low editing efficiency of GluR2 mRNA is associated with a low relative abundant of ADAR2 mRNA in white matter of normal human brain. Eur J Neurosci, 18:23-33, 2003
PubMed
28) Slavov D, Gardiner K:Phylogenetic comparison of the pre-mRNA adenosine deaminase ADAR2 genes and transcripts:conservation and diversity in editing site sequence and alternative splicing patterns. Gene 299:83-94, 2002
PubMed
29) The BDNF Study Group:A controlled trial of recombinant methionyl human BDNF in ALS(Phase III). Neurology 52:1427-1433, 1999
 
30) Klivenyi P, Ferrante RJ, Matthews RT, et al:Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5:347-350, 1999
 
P.152 掲載の参考文献
1) Aoki M, Ogasawara M, Matsubara Y, et al:Mild ALS in Japan associated with novel SOD mutation[published erratum appears in Nature Genet. 6:225, 1994. Nature Genet 5:323-324, 1993
 
2) Rosen DR, Siddique T, Patterson D, et al:Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59-62, 1993
PubMed
3) Deng HX, Hentati A, Tainer JA, et al:Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 261:1047-1051, 1993
PubMed
4) Gurney ME, Pu H, Chiu AY, et al:Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264:1772-1775, 1994
PubMed
5) Wong PC, Pardo CA, Borchelt DR, et al:An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14:1105-1116, 1995
PubMed
6) Bruijn LI, Becher MW, Lee MK, et al:ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18:327-338, 1997
PubMed
7) Nagai M, Aoki M, Miyoshi I, et al:Transgenic mice expressing an H46R mutation of human Cu/Zn superoxdde dismutase, Koji Abe (ed):Ecerpta Medica lnternational congress series 1221 Neurology, Molecular mechanism and therapeutics of amyotrophic lateral sclerosis, Elsevier, Amsterdam, pp273-279, 2000
 
8) Julien JP:Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell 104:581-91, 2001
PubMed
9) Niwa J, Ishigaki S, Hishikawa N, et al:Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity J Biol Chem 277:36793-36798, 2002
PubMed
10) Miyazaki K, Fujita T, Ozaki T, et al:NEDL1, a novel ubiquitin-protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1. J Biol Chem 279:11327-11335, 2004
PubMed
11) Aoki M, Ogasawara M, Matsubara Y, et al:Familial amyotrophic lateral sclerosis (ALS) in Japan associated with H46R mutation in Cu/Zn superoxide dismutase gene:a possible new subtype of familial ALS. J Neurol Sci 126:77-83, 1994
PubMed
12) Aoki M, Abe K, Houi K, et al:Variance of age at onset in a Japanese family with amyotrophic lateral sclerosis associated with a novel Cu/Zn superoxide dismutase mutation. Ann Neurol 37:676-679, 1995
 
13) Inoue H, Tsukita K, Iwasato T, et al:The crucial role of caspase-9 in the disease progression of a transgenic ALS mouse model. EMBO J 22:6665-6674, 2003
PubMed
14) Nagai M, Aoki M, Miyoshi I, et al:Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis:associated mutations develop motor neuron disease. J Neurosci 21:9246-9254, 2001
PubMed
15) Sun W, Funakoshi H, Nakamura T:Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci 22:6537-6548, 2002
 
P.157 掲載の参考文献
1) Munsat TL:Workshop report. International SMA Collaboration. Neuromusc Disord 1:81, 1991
 
2) Shishikura K:Peripheral nerves in Werdnig-Hoffmann disease. Neuropathology 5:325-326, 1984
 
3) Brzustowicz LM, Lehner T, Castilla LH, et al:Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature 344:540-541, 1990
 
4) Melki J, Abdelhak S, Sheth P, et al:Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature 344:767-768, 1990
PubMed
5) Kleyn PW, Wang CH, Lien LL, et al:Construction of a yeast artificial chromosome contig spanning the spinal muscular atrophy disease gene region. Proc Natl Acad Sci USA 90:6801-6805, 1993
PubMed
6) MacKenzie A, Roy N, Besner A, et al:Genetic linkage analysis of Canadian spinal muscular atrophy kindreds using flanking microsatellite 5q13 polymorphisms. Hum Genet 90:501-504, 1993
PubMed
7) Melki J, Lefebvre S, Bu..rglen L, et al:De novo and inherited deletions of the 5q13 region in spinal muscular atrophy. Science 264:1474-1477, 1994
 
8) Lefebvre S, Burglen L, Reboullet S, et al:Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155-165, 1995
PubMed
9) Roy N, Mahadevan MS, McLean M, et al:The gene for neuronal apoptosis inhibitory protein is partially deleted individuals with spinal muscular atrophy. Cell 80:167-178, 1995
PubMed
10) van der Steege G, Groorscholten PM, van der Vlies, et al:PCR-based DNA test to confirm clinical diagnosis of autosomal recessive spinal muscular atrophy. Lancet 345:985-986, 1995
 
11) 斎藤加代子, 伊藤万由里, 前田由美ほか:脊髄性筋萎縮症の 臨床と分子遺伝学. 東京女子医科大学雑誌 70:E2-E9, 2000
 
12) Burglen L, Seroz T, Miniou P, et al:The gene encoding p44, a subunit of the transcription factor TFIIH, is involved in large-scale deletions associated with Werdnig-Hoffmann disease. Am J Hum Genet 60:72-79, 1997
PubMed
13) Scharf JM, Endrizzi MG, Wetter A, et al:Identification of a candidate modifying gene for spinal muscular atrophy by comparative genomics. Nat Genet 20:83-86, 1998
PubMed
14) Didonato CJ, Ingraham SE, Mendell JR, et al:Deletion and conversion in spinal muscular atrophy patients:Is there a relationship to severity?Ann Neurol 41:230-237, 1997
 
15) Ito M, Saito K, Du Juan et al:J Tokyo Women's Med Univ 74:167-178, 2004
 
16) Liu Q & Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J 15:3555-3565, 1996
PubMed
17) Lefebvre S, Burlet P, Liu Q, et al:Correlation between severity and SMN protein level in spinal muscular atrophy. Nature Genet 16:265-269, 1997
PubMed
18) Coovert DD, Le TT, McAndrew PE, et al:The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet 6:1205-1214, 1997
PubMed
19) Burlet P, Huber C, Bertrandy S, et al:The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. Hum Mol Genet 7:1927-1933, 1998
PubMed
20) Pellizzoni L, Kataoka N, Charroux B, et al:A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 95:615-624, 1998
PubMed
21) Pelizzoni L, Yong J, Dreyfuss G:Essential role for the SMN complex in the specificity of snRNP assembly. Science 298:1775-1779, 2002
 
22) Schrank B, Gotz R, Gummersen JM, et al:Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci USA 94:9920-9925, 1997
 
23) Hsieh-Li HM, Chang J-G, Jong Y-J, et al:A mouse model for spinal muscular atrophy. Nature Genet 24:66-70, 2000
PubMed
24) Monani UR, Sendtner M, Coovert DD, et al:The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn-/-mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 9:333-339, 2000
 
25) Frugier T, Tiziano FD, Cifuentes-Diaz C, et al:Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy. Hum Mol Genet 9:849-858, 2000
 
26) Rudnik-Schoneborn S, Forkert R, Hahnen E, et al:Clinical spectrum and diagnostic criteria of infantile spinal muscular atrophy:Further delineation on the basis of SMN gene deletion findings. Neuropediatrics 27:8-15, 1996
PubMed
27) Rudnik-Schoneborn S, Sztriha L, Aithala GR, et al:Extended phenotype of pontocerebellar hypoplasia with infantile spinal muscularatrophy. Am J Med Genet 117A:10-17, 2003
 
28) Kausch K, Mu..ller CR, Grimm T, et al:No evidence for linkage of autosomal dominant proximal spinal muscular atrophies to chromosome 5q markers. Hum Genet 86:317-318, 1991
 
29) Grohmann K, Schuelke M, Diers A, et al:Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nature Genet 29:75-77, 2001
PubMed
30) Tanamy MG, Magal N, Halpern G J, et al:Fine mapping places the gene for arthrogryposis multiplex congenita neuropathic type between D5S394 and D5S2069 on chromosome 5qter. Am J Med Genet 104:152-156, 2001
PubMed

第7章 不随意運動の病態と治療

P.164 掲載の参考文献
1) Lang AE:Movement disorders symptomatology. In Neurology in Clinical Practice. (ed. Bradlwy WG, Daroff RB, Fenichel GM, et al)Butterworth-Heinemann, Massachusetts, p299-320, 1996
 
2) Obeso JA, Rothwell JC, Marsden CD:The spectrum of cortical myoclonus. From focal reflex jerks to spontaneous motor epilepsy. Brain 108:193-224, 1985
PubMed
3) Shibasaki H, Kuroiwa Y:Electroencephalographic correlates of myoclonus. Electroenceph Clin Neurophysiol 36:455-463, 1975
 
4) Uesaka Y, Terao Y, Ugawa Y, at el:Magnetoencephalographic analysis of cortical myoclonic jerks. Electroenceph Clin Neurophysiol 99:141-148, 1996
 
5) Mima T, Nagamine T, Ikeda A, et al:Pathogenisis of cortical myoclonus studied with magnetoencephalography. Neurology 50:598-607, 1998
 
6) Shibasaki H, Yamashita Y, Tobimatsu S, et al:Electroen-cephalographic correlates of myoclonus. Adv Neurol 43:357-372, 1986
 
7) Shibasaki H, Motonmra S, Yamashita Y, et al:Periodic synchronous discharge and myoclonus in Creutzfeldt-Jakob disease:diagnostic application of jerk-locked averaging method. Ann Neurol 9(2):150-156, 1981
 
8) Hallett M, Chadwick D, Adam J, et al:Reticular reflex myoclonus:a physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatry 40(3):253-264, 1977
PubMed
9) Brown P, Rothwell JC, Thompson PD, et al:Propriospinal myoclonus:evidence for spinal?pattern generators in humans. Mov Disord 9(5):571-576, 1994
PubMed
10) Meinck HM, Ricker K, Hulser PJ, et al:Stiff man syndrome:neurophysiological findings in eight patients. J Neurol 242:134-142, 1995
PubMed
11) Adams RD, Foley JM:The neurological changes in the more common types of severe liver disease. Trans Am Neurol Assoc 74:217-219, 1949
 
12) Shahani BT, Young RR:Asterixis-a disorders of the neural mechanisms underlying sustained contraction. In Shahani Med. The Motor system:Neurophysiology and Muscle Mechanisms. Amsterdam, Elsevier 301-306, 1976
 
13) Ugawa Y, Shimpo T, Mannen T:Physiological analysis of asterixis:silent period locked averaging. J Neurol Neurosurg Psychiatry 52:89-93, 1989
PubMed
14) Shibasaki H:Pathophysiology of negative myoclonus and asterixis. Adv Neurol 43:199-209, 1995
 
15) Zanducke MV:Treatment of myoclonus Acta Neurol Belg 103:66-70, 2003
 
16) Agarwal P, Frucht SJ:Myoclonus. Curr Opin Neurol 16(4):515-521, 2003
PubMed
17) Frucht S:Myoclonus. Curr Treat Options Neurol 2(3):231-242, 2000
PubMed
P.169 掲載の参考文献
1) 古川哲雄:続ヤヌスの顔 背面思考の神経内科学. 科学評論社, 東京, p145-149, 1992
 
2) McHenry LC Jr.:Garrison's History of Neurology, Charles C Thomas, Springfield, 1969 (豊倉康夫監訳:神経学の歴史. 医学書院, p33, 1977)
 
3) Huntington G:On chorea. Med Surg Rep 26:317, 1872
 
4) McHenry LC Jr.:Garrison's History of Neurology. Charles C Thomas, Springfield, 1969 (豊倉康夫監訳:神経学の歴史. 医学書院, P247-248, 1977)
 
5) Hammond W:A treatise on disease of the nervous system. Appleton D. New York, p654-662, 1871
 
6) Parkinson J:An essay on the shaking palsy. Whittingham & Rowland, London, 1817
 
7) 古川哲雄:ヤヌスの顔第4集.科学評論社, 東京, p36-40, 1992
 
8) 平山恵造:神経症候学.文光堂, 東京, p581, 1979
 
9) 岩田 誠:神経症候学を学ぶ人のために. 医学書院, 東京 p147-151, 1994
 
10) 柳澤信夫:不随意運動, 神経内科学書 第2版. (豊倉康夫, 萬年徹, 金沢一郎, 編), 朝倉書店, 東京, p137-144, 2004
 
11) DeLong MR:The basal ganglia. In:Principles of neural science (ed. Kandel ER, Schwartz JH & Jessel TM) McGraw-Hill, New York, p853-867, 2000
 
12) 向井栄-郎:Ballism, chorea, athetosis-相互関係, 鑑別-. 神経内科 54:107-113, 2001
 
13) Husby G, van de Rijn I, Zabriskie JB, et al:Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med 144:1094-1110, 1976
PubMed
14) Singer HS, Loiselle C, Lee O, et al:Anti-basal ganglia antibody abnormalities in Sydenham chorea, J Neuroimmunol 136:154-161, 2003
PubMed
15) Cervera R, Asherson RA, Font J, et al:Chorea in the antiphospholipid syndrome;clinical, radiolodic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine(Baltimore)76:203-212, 1997.
PubMed
16) Nausieda PA, Kollar WC, Weiner WJ, et al:Modification of postsynaptic dopaminergic sensitivity by female sex hormones. Life Sci 25:521-526, 1979
 
17) Cardoso F, Maia D, Cunningham Mc, et al:Treatment of Sydenham chorea with corticosteroids. Mov Disord 18:1374-1377, 2003
PubMed
18) 野村芳子:アテトーゼ, 神経症候群 II. 別冊日本臨床領域別症候群シリーズ 27, p108-111, 1999
 
P.176 掲載の参考文献
1) Eldridge R:The torsion dystonias:Literature review and genetic and clinical studies. Neurology 20 part 2:1-78, 1970
 
2) Yanagisawa N, Goto A:Dystonia musculorum deformans. Analysis with electromyography. J Neurol Sci 13:39-65, 1971
PubMed
3) Fahn S, Marsden CD, Calne DB:Classification and investigation of dystonia Marsden CD, Fahn S (ed):Movement Diserders 2. Butterworths, London, p332-358, 1987
 
4) 柳澤信夫:Dystonia と Athetosis. 神経研究の進歩 29:195-209, 1985
 
5) Segawa M, Hosaka A, Miyazawa F, et al:Hereditary progressive dystonia with marked diurnal fluctuation, Eldridge R, Fahn S (ed):Advances in Neurology vol 14:Dystonia Raven Press, New York, p215-233, 1976
 
6) 柳澤信夫:本態性ジストニーと症候性ジストニー. 最新医学 31:315, 1976
 
7) 柳澤信夫:不随意運動, Parkinson 病. Medicina20:851, 1983
 
8) 橋本隆男, 柳澤信夫, 進藤政臣:ジストニーに対する trihexyphenidyl 大量療法. 臨床神経学 24:769, 1984
 
9) Thompson PD:Writer's cramp. Br J Hosp Med 50:91-94, 1993
 
10) Lenz FA, Byl NN:Reorganization in the cutaneous core of the human thalamic principal somatic sensory nucleus (ventral caudal)in patients with dystonia. J. Neurophysiol 82:3204-3212, 1999
PubMed
11) Vercueil L, Krack P, Pollak P:Results of deep brain stimulation for dystonia:Acritical reappraisal. Mov Dis 17 (suppl 3):S89-S93, 2002
 
12) 柳澤信夫, 橋本隆男:ジストニア治療の展望. J Clinical Rehabilitation 10:119-124, 2001
Medical*Online
13) Fahn S:Treatment of dystonia with high dosage anticholinergic medication. Neurology 29:605, 1973
 
14) 橋本隆男, 柳澤信夫, 太田節子:ジストニアの薬物治療-全国アンケート調査集計結果-. 神経研究の進歩 31:873-883, 1987
 
15) Ohara S, Hayashi R, Momoi H, et al:Mexiletine in the treatment of spasmodic torticollis. Movement Disorders 13:934-940, 1998
 
16) Cooper IS:Involuntary Movement Disorders. Hoeber, New York. p131-292, 1969
 
17) Vitek JL:Pathophysiology of dystonia:a neuronal model. Movement Disorders 17(suppl 3):S49-S62, 2002
 
18) 柳澤信夫:ジストニアとは-概念, 症候, 分類-. 脳の科学 24:811-820, 2002
 
P.182 掲載の参考文献
1) 大江千廣:振戦の実験的研究.佐々木和夫, 本郷利憲, 編:新生理科学大系 [10] 運動の生理学, 医学書院, 東京, p243-256, 1998
 
2) Ohye C:Thalamotomy for Parkinson's disease and other types of tremor, Gildenberg PL, Tasker RR(ed):Textbook of Stereotactic and Functional Neurosurgery. McGraw-Hill, New York, p1167-1178, 1997
 
3) 大江千廣:振戦の神経機序. 神経進歩 25:106-117, 1981
 
4) Ohye C, Shibazaki T, Hirai T, et al:Further physiological observations on the ventralis intermedius neurons in the human thalamus. J Neurophysiol 61:488-500, 1989
 
5) 大江千廣:赤核症候群. 主としてその歴史的背景について. 現代医療 11:797-789, 1979
 
6) Poirier LJ, Bouvier G, Bedard P, et al:Essai sur les circuits neuronaux impliques dans le tremblement postural et l' hypokinesie. Rev Neurol 120:15-40, 1969
 
7) Deuschl G, Raethjen J, Baron R, et al:The pathophysiology of parkinsonian tremor:a review. J Neurol 247(suppl 5):v33-48, 2000
 
8) McAuley JH, Marsden CD:Physiological and pathological tremors and rhythmic central motor control Brain 123:1545-1567, 2002
 
9) Dostrovsky J, Bergman H:Oscillatory activity in basal ganaglia-relationshp to normal physiology and pathophysiology. Brain 127:721-722, 2004
 
10) Bevan MD, Magill PJ, Temman D, et al:Move to the rhythm:Oscillations in the subthalamic nucleus-external globus pallidus network. TINS 25:525-531, 2002
 
11) Deuschl G, Bain P, Brin M:Consensus statement of Movement Disorder Society on tremor. Ad hoc scientific committee. Mov Disord 13(suppl 3):2-23, 1998
 
12) 大江千廣:定位的視床破壊術. 駒井則彦編:定位脳手術 金芳堂, 京都, p219-231, 1999
 
13) Ohye C, Shibazaki T, Ishihara J, et al:Evaluation of gamma thalamotomy for parkinsonian and other tremors:survival of neurons adjacent to the thalamic lesion after gamma thalamotomy. J Neurosurg 93(suppl 3):120-127, 2000
 
14) Ohye C, Shibazaki T, Sato S:Thalamic lesion produced by gamma thalamotomy for movement disorders. J Neurosurg 97(suppl 5):600-606, 2002
 
15) 大江千廣, 柴崎 徹, 石原淳治, 他:不随意運動に対するガンマ視床手術の臨床経過と照射巣. 定位的放射線治療 5:67-73, 2001
 
P.185 掲載の参考文献
1) 坂本 崇, 梶 龍児:ボツリヌス療法の将来展望. 脳 215:420-423, 2002
 
2) 小熊恵二ほか:ボツリヌス毒素の構造と標的細胞に対する作用. 診断と治療 91:1231-1239, 2003
 
3) Comella CL, et al:Botulinum toxins in neurological disease. Masele Nerve 29:628-644, 2004
 

第8章 筋疾患とその治療

P.191 掲載の参考文献
1) Squire S, Raymackers JM, Vandebrouck C, et al:Prevention of pathology in mdx mice by expression of utrophin:analysis using an inducible transgenic expression system. Hum Mol Genet 11:3333-3344, 2002
PubMed
2) Barton-Davis ER, Cordier L, Shoturma DI, et al:Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104:375-381, 1999
PubMed
3) Dunant P, Walter MC, Karpati G, et al:Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 27:624-627, 2003
PubMed
4) Wagner KR, Hamed S, Hadley DW, et al:Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 49:706-711, 2001
PubMed
5) Politano L, Nigro G, Nigro V, et al:Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 22:15-21, 2003
PubMed
6) Takeshima Y, Yagi M, Ishikawa Y, et al:Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev 23:788-798, 2001
PubMed
7) van Deutekom JCT, Bremmer-Bout M, Janson, AAM, et al:Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol Genet 10:1547-1554, 2001
 
8) Aartsma-Rus A, Bremmer-Bout M, Janson A, et al:Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy Neuromuscul Disord 12(Suppl):S71-S77, 2002
 
9) Aartsma-Rus A, Janson AA, Kaman WE, et al:Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12:907-914, 2003
PubMed
10) Aartsma-Rus A, Janson AA, Kaman WE, et al:Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense, Am J Hum Genet 74:83-92, 2004
PubMed
11) Agus S, Tran VKY, Takshima H, et al:Chimeric RNA/ethylene bridged nucleic acids promote dystrophin expression in myocytes of Duchenne muscular dystrophy by inducing skipping of the nonsense-mutation-encoding exon. Hum Gene Ther
 
12) Yagi M, Takeshima Y, Sununo A, et al:Chimeric RNA and 2'-O, 4'-C-ethylene-bridged nucleic acids have stronger activity than phosphorothioate oligodeoxynucleotides in induction of exon-19 skipping in dystropin mRNA. Oligonucleotides 14:33-40, 200
 
P.195 掲載の参考文献
1) 神野 進:筋ジストロフィーのステロイド療法, 先端医療シリーズ14神経・筋疾患の最新医療, 先端医療技術研究所, 東京, p247-251, 2001
 
2) Brooke MH, Fenichel GM, Griggs RC, et al:Clinical investigation of Duchenne muscular dystrophy;Interesting results in a trial of prednisone. Arch Neurol 44:812-817, 1987
 
3) Mendell JR, Moxley RT, Griggs RC, et al:Randomized double-blind six-month trial of prednisone in Duchenne muscular dystrophy. N Eng J Med 320:1592-1597, 1989
 
4) Griggs RC, Moxley RT, Mendell JR, et al.:Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response, Arch Neurol 48:383-388, 1991
PubMed
5) Sansome A, Royston P, Dubowitz V:Steroids in Duchenne muscular dystrophy;Pilot study of a new low-dose schedule. Neuromuscul Disord 3:567-569, 1993
 
6) Connolly AM, Schierbecker J, Renna R, et al:High dose weekly oral prednisolone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 12:917-925, 2002
PubMed
7) Merlini L, Cicognani A, Malaspina E, et al:Early prednisolone treatment in Duchhenne muscular dystrophy. Muscle and Nerve 27:222-227, 2003
 
8) Kissel JT, Burrow K, Rammohan KW, et al:Mononuclear cell analysis of muscle biopsies in prednisone treated and untreated Duchenne muscular dystrophy. Neulogy 41:667-672, 1991
 
9) Pasquini F, Guerin C, Blake D, et al:The effects glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cell. Neuromuscul Disord 5:105-114, 1995
PubMed
10) Tawil R, McDermott MP, Pandya S, et al:Apilot trial of prednisone facioscapulohumeral muscular dystrophy. Neulogy 48:46-49, 1997
 
11) Connolly AM, Pestronk A, Mehta S, et al:Primary a-sarcoglycan defiency response to immunosupression over three years. Muscle and Nerve 21:1549-1553, 1998
 
12) Tarnopolsky MA, Roy BD, MacDonald JR:A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle and Nerve 20:1502-1509, 1997
PubMed
13) Tarnopolsky M, Martin J:Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 52:854-857, 1999
PubMed
14) Walter MC, Lochmuller H, Reilich P et al:Creatine monohydrate in muscular dystrophies. A double-blind, placebo-controlled clinical study. Neurology 54:1848-1850, 2000
PubMed
15) Louis M, Lebacq J, Poortmans JR, et al:Beneficial effect of creatine supplementation in dystrophic patients. Muscle and Nerve 27:604-610, 2003
PubMed
16) Tarnopolsky MA, Mahoney DJ, Vajsar J, et al:Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 62:1771-1777, 2004
PubMed
17) Pulido SM, Passaquin AC, Leijendekker WJ, et al:Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Lett 439:357-362, 1998
PubMed
18) Parise G, Mihic S, MacLennan D, et al:Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. J Appl Physiol 91:1041-1047, 2001
PubMed
19) Lawler JM, Barnes WS, Wu G, et al:Direct antioxidant properties of creatine. Biochem Biophys Res Commun 290:47-52, 2002
PubMed
20) Maltin CA, Delay MI:Satellite cells in innervated and denervated muscles treated with clenbuterol. Muscle and Nerve 15:919-925, 1992
 
21) Heaketh JE, Campbell GP, Lobley GE, et al:Stimulation of actin and myosin synthesis in rat gastrocnemius muscle by clenbuterol:evidence for translational control. Comp Biochem Physiol 102:23-27, 1992
 
22) Benson DW, Foley-Nelson T, Chance WT, et al:Decreased myofibrillar protein breakdown following treatment with clenbuterol. J Surg Res 50:1-5, 1991
PubMed
23) Rothwell NJ, Stock MJ:Modification of body composition by clenbuterol in normal dystrophic (mdx) mice. Biosci Rep 5:755-760, 1985
PubMed
24) Kissel JT, McDermott. MP, Natarajan R, et al:Pilot trial of albuterol in facioscapilohumeral muscular dystrophy. Neurology 50:1402-1406, 1998
PubMed
25) Kissel JT, McDermott MP, Mendell JR, et al:Randomized, doubl-blind, placebo-controlled trial of albuterol in facioscapilohumeral muscular dystrophy, Neurology 57:1434-1440, 2001
 
26) 大村 清, 鴻巣 武:顔面肩甲上腕型筋ジストロフィー患者 の筋力およびADLの改善に対するプロカテロールの効果. 脳と発達 32(suppl):266, 2000
Medical*Online
27) Fowler EG, Graves MC, Wetzel GT, et al:Pilot trial of albuterol in Duchenne muscular dystrophy. Neurology 62:1006-1008, 2004
PubMed
28) 田村拓久, 澁谷統壽, 飯田光男ら:Duchenne型筋ジストロフィー患者の慢性心機能障害に対するカプトリル治療の臨床評価.臨床医薬 12:3635-3646, 1996
 
29) Bristow MR, Gilbert EM, Abraham WT, et al:Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94:2807-2816, 1996
PubMed
30) Australia/New Zealand Heart Failure Research Collaborative Group:Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 349:375-380, 1997
 
31) Cittadini A, Ines Comi L, Longobardi S, et al:A preliminaly randomized study of growth hormone administration ill Becker and Duchenne muscular dystrophies. Eur Heart J 24:664-672, 2003
 
P.202 掲載の参考文献
1) 岩下 宏, 川井 充 (厚生省精神・神経疾患研究委託費 筋ジストロフィー患者のQOLの向上に関する総合研究班 班長) 編:筋強直性ジストロフィーの治療とケア, 医学書院, 東京, 2000
 
2) van den Broek WJ, Nelen MR, Wansink DG, et al:Somatic expansion behaviour of the (CTG) n repeat in myotonic dystrophy knock-in mice is differentially affected by Msh3 and Msh6 mismatch-repair proteins. Hum Mol Genet 11:191-198, 2002
PubMed
3) Ranum LP, Day JW:Myotonic dystrophy:RNA pathogenesis comes into focus. Am J Hum Genet 74:793-804, 2004
PubMed
4) Mankodi A, Logigian E, Callahan L, et al:Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289:1769-1773, 2000
PubMed
5) Mankodi A, Takahashi MP, Jiang H, et al:Expanded CUG repeats trigger aberrant splicing of CIC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 10:35-4, 2002
 
6) Kanadia RN, Johnstone KA, Mankodi A, et al:A muscleblind knockout model for myotonic dystrophy. Science 302:1978-1980, 2003
PubMed
7) Ho TH, Charlet-B N, Poulos MG, et al:Muscleblind proteins regulate altemative splicing. EMBO J 23:3103-3112, 2004
 
8) Amack JD, Mahadevan MS:Myogenic defects in myotonic dystrophy. Dev Biol 265:294-301, 2004
PubMed
9) Finsterer J:Myotonic dystrophy type 2. Eur J Neurol 9:441-447, 2002
PubMed
10) Le Ber I, Martinez M, Campion D, et al:Anon-DMI, non-DM2 multisystem myotonic disorder with frontotemporal dementia:phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24. Brain 127:1979-1992, 2004
 
11) 松村 剛, 横江 勝, 中森雅之ほか:筋ジストロフィー患者 におけるクレアチン療法の試み. 臨床神経 (in press)
 
12) 中山貴博, 山本敦子, 内山 剛ほか:筋強直性ジストロフィーの呼吸調節機能異常. 臨床神経 39:1006-1009, 1999
 
13) Lazarus A, Varin J, Babuty D, et al:Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing:a multicenter diagnostic pacemaker study. J Am Coll Cardiol 40:1645-1652, 2002
PubMed
14) 村橋 真, 澁谷誠二, 高橋丈二ほか:筋強直性ジストロフィーの嚥下障害に対する phenytoin の効果:videofluorography による検討. 神経治療 18:163-167, 2001
 
15) 松村 剛, 野崎園子, 横江 勝ほか:筋強直性ジストロフィーでは子宮筋腫合併率が高い. 医療 56:472-475, 2002
Medical*Online
16) 日浅友希, 河野昌史, 謝 宗安ほか:筋強直性ジストロフィー患者における周術期管理. 神経内科 60:405-410, 2004
 
P.208 掲載の参考文献
1) Fukuyama Y, Osawa M, Suzuki H:Congenital Progressive muscular dystrophy of the Fukuyama type-clinical, genetic and pathological considerations. Brain Dev 3:1-29, 1981
PubMed
2) Toda T, Segawa M, Nomura Y, et al:Localization of a gene for Fukuyama type congenital muscular dystrophy to chromosome 9q31-33. Nat Genet 5:283-286, 1993
PubMed
3) Kobayashi K, Nakahori Y, Miyake M, et al:An ancient retrotransposal insertion causes Fukuyam-type congenital muscular dystrophy. Nature 394:388-392, 1998
 
4) Kondo-Iida E, Kobayashi K, Watanabe M, et al:Novel mutations and genotype-phenotype relationships in 107 families with Fukmyama-type congenital muscular dystrophy (FCMD). Hum Mol Genet 8:2303-2309, 1999
PubMed
5) Silan F, Yoshioka M, Kobayashi K, et al:A new mutation of the fukutin gene in a non-Japanese patient. Ann Neurol 53:392-396, 2003
 
6) Beltran-Valero de Bernabe D, van Bokhoven H, van Beusekom E, et al:A homozygous nonsense mutation in the Fukmtin gene causes a Walker-Warburg syndrome phenotype. J Med Genet 40:845-848, 2003
 
7) Hayashi YK, Ogawa M, Tagawa K, et al:Selective deficiency of α-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 57:115-121, 2001
 
8) Michele DE, Barresi R, Kanagawa M, et al:Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418:417-422, 2002
PubMed
9) Nakano I, Funahashi M, Takada K, et al:Are breaches in the glia limitans the primary cause of the micropolygyria in Fukuyama-type congenital muscular dystrophy (FCMD)? Pathological study of the cerebral cortex of an FCMD fetus. Acta Neuropathol g l:313-321, 1996
 
10) Moore SA, Saito F, Chen J, et al:Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature 418:422-425, 2002
PubMed
11) Yoshida A, Kobayashi K, Manya H, et al:Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 1:717-724, 2001
 
12) Taniguchi K, Kobayashi K, Saito K, et al:A worldwide distribution and a broader clinical spectrum of muscle-eye-brain disease. Hum Mol Genet 12:527-534, 2003
 
13) Beltran-Valero de Bernabe D, Currier S, Steinbrecher A, et al:Mutation in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg Syndrome. Am J Hum Genet 71:1033-1043, 2002
 
14) Grewal PK, Holzfeind PJ, Bittner RE, et al:Mutant glycosyltransferase and altered glycosylation of α-dystroglycan in the myodystrophy mouse. Nat Genet 28:151-154, 2001
 
15) Longman C, Brockington M, Torelli S, et al:Mutation in the human LARGE gene cause MDCID, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of α-dystroglycan. Hum Mol Genet 12:2853-2861, 2003
 
16) Brockington M, Blake DJ, Prandini P, et al:Mutation in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin α 2 deficiency and abnormal glycosylation of a-dystroglycan. Am J Hum Genet 69:1198-1209, 2001
 
17) Kano H, Kobayashi K, Herrmann R, et al:Deficiency of α-dystroglycan in muscle-eye-brain disease. Biochem Bi
 
18) Barresi R, Michele DE, Kanagawa M, et al:LARGE can functionally bypass α-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat Med 10:696-703, 2004
 

第9章 末梢神経疾患と治療

P.214 掲載の参考文献
1) Waxmann SG:Voltage-gated ion channels in axons:Localization, function, and development. Waxmann SG, Kocsis JD, Stys PK eds:The axon. Oxford University Press, New York, p218-243, 1995
 
2) Howe JR, Ritchie JM:Sodium currents in Schwann cells from myelinated and non-myelinated nerves of neonatal and adult rabbits. J Physiol 425:169-210, 1990
PubMed
3) Caldwell JH, Schaller KL, Lasher RS et al:Sodium channel Nav1.6 is located at nodes of Ranvier, dendrites, and synapses. Oric Natl Acad Sci USA 97:5616-5620, 2000
 
4) Girault JA, Peles E:Development of Ranvier. Current Opinion in Neurobiology 12:476-485, 2002
PubMed
5) Boiko T, Rasband MN, Rock S, et al:Compact myelin dictates the differential targeting of two sodium channe isoforms in the same axon. Neuron 30:91-104, 2001
 
6) Burke D, Kiernan C, Bostock H:Excitability of human axons. Clin Neurophysiol 112:1575-1585, 2001
 
7) Bostock H, Rothwell JC:Latent addition in motor and sensory fibers of human peripheral nerve. J Physiol 498:277-294, 1997
PubMed
8) Tokuno HA, Kocsis JD, Waxmann SG:Noninactivating, tetrodotoxin-sensitive Na+conductance in peripheral axons. Muscle Nerve 28:212-217, 2003
 
9) Novakovic SD, Levinson SR, Schachner M, et al:Disruption and reorganization of sodium channels in experimental allergic neuritis. Muscle Nerve 21:1019-1032, 1998
PubMed
10) Arimura K, Sonoda Y, Watanabe O, et al:Ion channel disorders in neuropathy. Advance in clinical neurophysiology. Reisin RC ed, Nuwer MR, Hallett et al. eds. Elsevier, Tokyo, p43-48, 2002
 
11) Waxman SG:Acquired channelopathies in nerve injury and MS. Neurology 56:1621-1627, 2001
PubMed
12) Barker M, Bostock O, Grafe P, et al:Function and distribution of three types of rectifying channel in rat spinal root myelinated axons. J Physiol 383:45-67, 1987
 
13) Browne DL, Gancher ST, Nutt JG, et al:Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nature Genetics 8:136-140, 1994
PubMed
14) Chiu SY, Zhou L, hang C-L, et al:Analysis of potassium channel functions in mammalian axons by gene knockouts. J Neurocyt 28:349-364, 1999
 
15) Hart IK, Waters C, Vincent A et al:Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 41:238-246, 1997
PubMed
16) Arimura K, Sonoda Y, Watanabe O, et al:Isaacs' syndrome as a potassium channelopathy of the nerve. Muscle Nerve (suppl) 11:55-58, 2002
 
17) 有村公良, 園田至人:Isaacs 症候群:チャンネル病. 脳の科学 21 (増):147-151, 1999
 
18) Torbergsen T, Stalberg E, Brautaset NJ:Generator sites for spontaneous activity in neuromyotonia. An EMG study. Electroencephalogr Clin Neurophysiol 101:69-78, 1996
 
P.218 掲載の参考文献
1) Bostock H, Sharief MK, Reid G, et al:Axonal ion channel dysfunction in amyotrophic lateral sclerosis. Brain 118:217-225, 1995
PubMed
2) Bostock H, Cikurel K, Burke D:Threshold tracking technique in the study of human peripheral nerve. Muscle Nerve 21:137-158, 1998
 
3) Burke D, Kiernan MC, Bostock H:Excitability of human axons. Clin Neurophysiol 112:1575-1585, 2001
PubMed
4) Bostock H, Rothwell JC:Latent addition in motor and sensory fibres of human peripheral nerve. J Physiol (Lond) 498:277-294, 1997
PubMed
5) Mogyoros I, Kiernan MC, Burke D:Strength-duration properties of human peripheral nerve. Brain 119:439-447, 1996
PubMed
6) Mogyoros I, Kiernan MC, Burke D, et al:Strength-duration properties of sensory and motor axons in patients with amyotrophic lateral sclerosis. Brain 121:851-859, 1998
PubMed
7) Kuwabara S, Kanai K, Sung J-Y, et al:Axonal hyperpolarization associayed with acute hypokalemia:multiple excitability measurements as indicators of the membrane potential of human axons. Muscle Nerve 26:283-287, 2002
 
8) Kiernan MC, Walters RL, Andersen KV, et al:Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain 125:1366-1378, 2002
 
9) Kanai K, Kuwabara S, Arai K, et al:Muscle cramp in Machado-Joseph disease:altered motor axonal excitability properties and mexiletine treatment. Brain 126:965-973, 2003
PubMed
10) Sima AAF:Metabolic alternations of peripheral nerve in diabetes. Semin Neurol 16:129-137, 1996
 
11) Misawa S, Kuwabara S, Ogawara S, et al:Hyperglycemia alters refractory periods in human diabetic neuropathy. Clin Neurophysiol 2004 a(in press)
 
12) Misawa S, Kuwahara S, Ogawa K, et al:Strength-duration properties and glycemic control in human diabetic motor nerves. Clin Neurophysiol 2004 b(in press)
 
P.224 掲載の参考文献
1) Asbury AK, McKhann GM:Changing views of Guillain-Barre syndrome. Ann Neurol 41:287-288, 1997
PubMed
2) Kusunoki S:Antiglycolipid antibodies in Guillain-Barre syndrome and autoimmune neuropathies. Am J Med Sci 319:234-239, 2000
PubMed
3) Kusunoki S, Morita D, Ohminami S, et al:Binding of immunoglobulin G antibodies in Guillain-Barre syndrome sera to a mixture of GM 1 and a phospholipid:possible clinical implications. Muscle Nerve 27:302-306, 2003
 
4) Chiba A, Kusunoki S, Obata H, et al:Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome:Clinical and immunohistochemical studies. Neurology 43:1911-1917, 1993
PubMed
5) Kaida K, Kusunoki S, Kanzaki M, et al:Anti-GQ1b antibody as a factor predictive of mechanical ventilation in Guillain-Barre syndrome. Neurology 62:821-824, 2004
PubMed
6) Kusunoki S, Chiba A, Kon K, et al:N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barre syndrome. Ann Neurol 35:570-576, 1994
 
7) Kaida K, Kusunoki S, Kamakura K, et al:GaINAc-GD1a in human peripheral nerve:Target sites of anti-ganglioside antibody. Neurology 61:465-470, 2003
 
8) Yuki N, Taki T, Inagaki F, et al:A bacterium lipopolysaccha-ride that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 178:1771-1775, 1993
 
9) Kusunoki S, Shiina M, Kanazawa I:Anti-Gal-C antibodies in GBS subsequent to mycoplasma infection:evidence of molecular mimicry. Neurology 57:736-738, 2001
 
10) Saida T, Saida K, Dorfman SH, et al:Experimental allergic neuritis induced by sensitization with galactocerebroside. Science 204:1103-1106, 1979
PubMed
11) Kusumoki S, Shimizu J, Chiba A, et al:Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurology 39:424-431, 1996
 
12) Yuki N, Yamada M, Koga M, et al:Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49:712-720, 2001
PubMed
13) Hughes RAC, Hadden RDM, Gregson NA, et al:Pathogenesis of Guillain-Barre syndrome. J Neuroimmunol 100:74-97, 1999
 
14) Plasma Exchange/Sandoglobulin Guillain-Barre syndrome trial group:Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 349:225-230, 1997
PubMed
15) Kieseier BC, Dalakas MC, Hartung H-P:Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 59 (Suppl 6):S7-S12, 2002
 
16) Toyka KV, Gold R:The pathogenesis of CIDP, Rationale for treatment with immunomodulatory agents. Neurology 60 (Suppl 3):S2-S7, 2003
 
17) Yan WX, Archelos JJ, Hartung HP, et al:PO protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:286-92, 2001
 
18) Shiina M, Kusunoki S, Miyazaki T, et al:Variability in immunohistochemistries of IgM M-proteins binding to sulfated glucuronyl paragloboside, J Neuroimmunol 116:206-212, 2001
PubMed
P.230 掲載の参考文献
1) Hattori N, Yamamoto M, Yoshihara T, et al:Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32):A clinicopathologic study of 205 Japanese patients. Brain 126:134-151, 2003
PubMed
2) Kiyosawa H, Lensch MW, Chance PF:Analysis of the CMT1A-REP repeat:mapping crossover breakpoints in CMT1A and HNPP. Hum Mol Genet 4:2327-2336, 1995
PubMed
3) Yamamoto M, Yasuda T, Hayasaka K, et al:Locations of crossover breakpoints within the CMT1A-REP repeat in Japanese patients with CMT1A and HNPP. Hum Genet 99:151-154, 1997
PubMed
4) Yamamoto M, Keller MP, Yasuda T, et al:Clustering of CMT1A duplication breakpoints in a 700 bp interval of the CMT1A-REP repeat. Hum Mutat 11:109-113, 1998
 
5) Hayasaka K, Himoro M, Sato W, et al:Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin PO gene. Nat Genet 5:31-34, 1993
 
6) Street VA, Bennett CL, Goldy JD, et al:Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 60:22-26, 2003
PubMed
7) Zhao C, Takita J, Tanaka Y, et al:Charcot-Marie-Tooth disease type 2A caused by mutation in a mictotubule motor KIF1B β. Cell 105:587-597, 2001
 
8) Mersiyanova IV, Perepelov AV, Polyakov AV, et al:A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 67:37-46, 2000
PubMed
9) Yamamoto M, Yoshihara T, Hattori N, et al:Glu528del in NEFL is a polymorphic variant rather than a disease-causing mutation for Charcot-Marie-Tooth disease in Japan. Neurogenetics 5:75-77, 2003
PubMed
10) Yoshihara T, Kanda F, Yamamoto M, et al:A novel missense mutation in the early growth response 2 gene associated with late-onset Charcot-Marie-Tooth disease type 1. J Neurol Sci 184:149-153, 2001
 
11) Guilbot A, Williams A, Ravise N, et al:A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease. Hum Mol Genet 10:415-421, 2001
PubMed
12) Bolino A, Muglia M, Confoti FL, et al:Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat Genet 25:17-19, 2000
 
13) Kalaydjieva L, Gresham D, Gooding R, et al:N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Am J Hum Genet 67:47-58, 2000
PubMed
14) Senderek J, Bergmann C, Weber S, et al:Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet 12:349-356, 2003
PubMed
15) Baxter RV, Ben Othmane K, Rochelle JM, et al:Ganglioside-induced differentiation-associated protein-1 is mutated in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet 30:21-22, 2002
PubMed
16) Sereda MW, Meyer zu Horste G, Suter U, et al:Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 9:1533-1537, 2003
 
17) Passage E, Norreel JC, Noack-Fraissignes P, et al:Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10:396-401, 2004
PubMed
18) Ohmori H, Ando Y, Makita Y, et al:Common origin of the Va130Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy. J Med Genet 41:e51, 2004
 
19) Misu K, Hattori N, Nagamatsu M, et al:Late-onset familial amyloid polyneuropathy type I (transthyretin Met 30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain 122:1951-1962, 1999
PubMed
20) Ikeda S, Nakazato M, Ando Y, et al:Familial transthyretin-type amyloid polyneuropathy in Japan:clinical and genetic heterogeneity. Neurology 58:1001-1007, 2002
PubMed
21) Koike H, Misu K, Ikeda S, et al:Type I(transthyretin Met30) familial amyloid polyneuropathy in Japan:early-vs late-onset form. Arch Neurol 59:1771-1776, 2002
PubMed
22) Koike H, Misu K, Sugiura M, et al:Pathologic difference of early-vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63:129-138, 2004
PubMed
23) Ando E, Ando Y, Haraoka K:Ocular amyloid involvement after liver transplantation for polyneuropathy. Ann Intern Med 135:931-932, 2001
PubMed
24) Umehara F, Tate G, Itoh K, et al:A novel mutation of desert hedgehog in a patient with 46, XY partial gonadal dysgenesis accompanied by minifascicular neuropathy. Am J Hum Genet 67:1302-1305, 2000
 
25) Date H, Onodera O, Tanaka H, et al:Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. Nat Genet 29:184-188, 2001
 
26) Takashima H, Nakagawa M, Nakahara K, et al:A new type of hereditary motor and sensory neuropathy linked to chromosome 3. Ann Neurol 41:771-780, 1997
PubMed
27) Takashima H, Boerkoel CF, John J, et al:Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet 32:267-272, 2002
PubMed
P.237 掲載の参考文献
1) Burke D, Kiernan MC, Bostock H:Excitability of human axons. Clin Neurophysiol 112:1575-1585, 2001
PubMed
2) Bostock H, Cikurel K, Burke D:Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 21:137-158, 1998
 
3) Lewis RA, Summer AJ, Brown MJ, et al:Multifocal demyelmating neuropathy with persistent conduction block Neurology 32:958-964, 1982
 
4) Kaji R, Oka N, Tsuji T, et al:Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol 33:152-158, 1993
PubMed
5) Kaji R, Hirota N, Oka N, et al:Anti-GM1 antibodies and impaired blood-nerve barrier may interfere with remyelination in multifocal motor neuropathy. Muscle Nerve 17:108-110, 1994
PubMed
6) Hirota N, Kaji R, Bostock H, et al:The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Brain 120 (Pt 12):2159-2169, 1997
 
7) Mezaki T, Kaji R, Kimura J:Multifocal motor neuropathy and Lewis Sumner syndrome:a clinical spectrum. Muscle Nerve 22:1739-1740, 1999
PubMed
8) Kaji R, Bostock H, Kohara N, et al:Activity-dependent conduction block in multifocal motor neuropathy. Brain 123 (Pt 8):1602-1611, 2000
 
9) Kiernan MC, Guglielmi JM, Kaji R, et al:Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 125:664-675, 2002
PubMed
10) Kaji R:Physiology of conduction block in multifocal motor neuropathy and other demyelinating neuropathies. Muscle Nerve 27:285-296, 2003
PubMed
11) Bostock H, Baker M, Reid G:Changes in excitability of human motor axons underlying post-ischaemic fasciculations:evidence for two stable states. J Physiol 441:537-557, 1991
 
12) Nodera H, Bostock H, Kuwabara S, et al:Nerve excitability properties in Charcot-Marie-Tooth disease type 1A. Brain 127:203-211, 2004
PubMed
13) Yang Q, Kaji R, Takagi T, et al:Abnormal axonal inward rectifier in streptozocin-induced experimental diabetic neuropathy. Brain 124:1149-1155, 2001
PubMed
14) Cappelen-Smith C, Kuwabara S, Lin CS, et al:Membrane properties in chronic inflammatory demyelinating polyneuropathy. Brain 124:2439-2447, 2001
PubMed
15) Kanai K, Kuwabara S, Arai K, et al:Muscle cramp in Machado-Joseph disease:altered motor axonal excitability properties and mexiletine treatment. Brain 126:965-973, 2003
PubMed

第10章 神経感染症

P.242 掲載の参考文献
1) Salahuddin SZ, Ablashi DV, Markham PD, et al:Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 234:596-601, 1986
PubMed
2) Yamanishi K, Okuno T, Shiraki K, et al:Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1:1065-1067, 1988
PubMed
3) Asano Y, Yoshikawa T, Suga S, et al:Vireimia and neutralizing antibody response im infants with exanthem subitum. J Pediatr 114:535-539, 1989
PubMed
4) Yoshikawa T, Suga S, Asano Y, et al:Distribution of antibodies to acausative agent of exanthem subitum (human herpesvius-6) in healthy individuals. Pediatrics 84:675-677, 1989
 
5) Asano Y, Yoshikawa T, Suga S, et al:Clinical features of infants with primary human herpesvirus 6 infection (exanthen subitum, roseola infantum). Pediatrics 93:104-108, 1994
PubMed
6) Yoshikawa T:Human herpervirus 6 infection in hematopoietic stem celltransplant patients. Brit J Haematol 124:421-432, 2004
 
7) Kondo K, Nagafuji H, Hata A et al:Association of human herpesvirus 6 infection of the central nervous system with recurrence of febrile convulsions. J Infect Dis 167:1197-1200, 1993
PubMed
8) Suga S, Suzuki K, Ihira M, et al:Clinical characteristics of febrile convulsions during primary HHV-6 infection. Arch Dis Child 82:62-66, 2000
PubMed
9) Maclean HJ, Douen AG:Severe amnesia associated with human herpesvirus 6 encephalitis after bone marrow transplmitation. Transplantation 73:1086-1089, 2002
PubMed
10) Drobyski WR, Knox KK, Majewski D, et al:Brief report:fatal encephalitis due to variant B human herpesvirus 6 infection in a bone marrow-transplant recipient. N Engl J Med 330:1356-1360, 1994
 
11) Yoshikawa T, Asano Y, Akimoto S, et al:Latent infection of human herpesvirus 6 in astrocytoma cell line and alteration of cytokine synthesis. J Med Virol 66:497-505, 2002
PubMed
12) Wu CA, Shanley JD:Chronic infection of human umbilical vein endothelial cells by human herpesvirus-6. J Gen Virol 79:1247-1256, 1998
PubMed
13) Ihira M, Yoshikawa T, Enomoto Y, et al:Rapid diagnosis of human herpesvirus 6 infection by a novel DNA amplification method, loop-mediated isothermal amplification. J Clin Microbiol 42:140-145, 2001
 
14) Cole PD, Stiles J, Boulad F, et al:Successful treatment of human herpesvirus 6 encephalitis in a bone marrow transplant recipient. Clin Infect Dis 27:653-654, 1998
 
15) Yoshihara S, Kato R, Inoue T, et al:Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient. who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. Transplantation 77:835-838, 2004
 
P.249 掲載の参考文献
1) 楠原智彦, 庄司紘史, 加地正英ほか:非ヘルペス性急性辺縁系脳炎の存在について. 臨床神経 34:1083-1088, 1994
 
2) 庄司紘史, 浅岡京子, 山本寛子ほか:非ヘルペス急性辺縁系脳炎. 神経内科 59:9-13, 2003
 
3) 西村敏樹, 三木健司, 小川克彦ほか:無菌性非ヘルペスウイルス性急性脳炎の病態-若年女性に起こり, 強い意識障害と遷延性経過を示すが転帰比較的良好な1群について-. Neuro-infection 2:74-76, 1997
 
4) 亀井 聡, 東郷将希, 三木健司ほか:若年女性に好発する急性非ヘルペス性脳炎の臨床像の検討. 神経内科59:173-178, 2003
 
5) 亀井 聡:若年女性に好発する急性非ヘルペス性脳炎 (Acute Juvenile Female Non-Herpetic Encephalitis:AJFNHE).神経研究の進歩:2004 (in press)
 
6) Buckley C, Oger J, Clover L, et al:Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50:73-78, 2001
PubMed
7) 細矢光亮, 法化図陽-:非ヘルペス性辺縁系脳炎とエンテロウイルス. 神経内科 59:25-30, 2003
 
8) 高橋輝行, 亀井 聡, 三木健司ほか:非ヘルペス性急性辺縁 系脳炎 (NHALE) の自験2例における髄液サイトカインの検討. 臨床神経学 43:162-169, 2003
 
9) Asaoka K, Shoji H, Nishizaka S, et al:Non-herpetic acute limbic encephalitis:cerebrospinal fluid cytokines and magnetic resonance imaging findings. Intern Med 43:42-48, 2004
PubMed
10) Sobin A, Ozer MN:Mental disorders in acute encephalitis. J Mt Saini Hosp 33:73-82, 1966
 
11) Brainin M, Presslich O, Eichberger G, et al:Akute virale Enzephalitis mit primar psychotischer Symptomatik-Diagnose, Verlauf und Prognose. Fortschr Neurol Psychiat 50:387-395, 1982
PubMed
12) Iizuka R:Beitrag zur akuten diffusen lymphocyt_ren Meningoencephalitis und Encephalopathie. Arch Psychiat Nervenkr 206:705-717, 1965
 
13) 森 昌忠, 竹島多賀夫, 荒賀 茂ほか:健常成人に見られた サイトメガロウイルス脳炎の一例. Neuro-infection 2:69-71, 1997
 
14) 平山幹生, 得田 彰, 武藤多津郎ほか:精神症状と意識障害で発症し, 予後良好なコクサッキーウイルスB4による脳炎の若年女性例. 臨床神経 38:60-62, 1998
 
15) Rogers SW, Andrews PI, Gahring LC, et al:Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 265 (5172):648-651, 1994
 
16) Takahashi Y, Mori H, Mishina M, et al:Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua. Neurology 61:891-896, 2003
PubMed
17) 成川孝一, 長谷川隆文, 武田 篤ほか:難治性の情動障害に対しセロトニン系賦活剤が有効であった非ヘルペス性辺縁系脳炎の1例. 臨床神経 41:805-808, 2001
 
P.254 掲載の参考文献
1) Sacktor N:The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 8 (suppl 2):115-121, 2002
 
2) Neuenburg JK, Brodt HR, Herndier BG, et al:HIV-related neuropathology, 1985 to 1999:Rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31:171-177, 2002
PubMed
3) Jellinger KA, Setinek U, Drlicek M, et al:Neuropathology and general autopsy findings in AIDS during the last 15 years. Acta Neuropathol 100:213-220, 2000
PubMed
4) Gray F, Chretien F, Vallat-Decouvelaere AV, et al:The changing pattern of HIV neuropahology in the HAART era. J Neuropahol Exp Neurol 62:429-440, 2003
PubMed
5) Langford TD, Letendre SL, Larrea GL, et al:Changing pattems in the neuropathogenesis of HIV during the HAART era. Brain Pathol 13:195-210, 2003
 
6) Langford D, Masliah E:Crosstalk between components of the blood brain barrier and cells of the CNS in microglial activation in AIDS. Brain Pathol 11:306-312, 2001
PubMed
7) Lawrence DM, Major EO:HIV-1 and the brain:connections between HIV-1-associated dementia, neuropathology and neuroimmunology. Microbes Infect 4:301-308, 2002
PubMed
8) Albright AV, Soldan SS, Gonzalez-Scaramo F:Pathogenesis of human immunodeficiency virus-induced neurological disease. J Neurovirol 9:222-227, 2003
 
9) McArthur JC, Haughey N, Gartner S, et al:Human immunoideficiency virus-associated dementia:an evolving disease. J Neurovirol 9:205-221, 2003
 
10) 岸田修二:HAART療法後のHIV脳症. 脳神経 56:301-310, 2004
 
11) Kusdra L, McGuire D, Pullium L:Changes in monocyte/macrophage neurotoxicity in the era of HAART:implications for HIV-associated dementia. AIDS 16:31-38, 2002
 
12) Garden GA, Budd SL, Tsai E, et al:Caspase cascades in human iminunodeficiency virus-associated neurodegeneration. J Neurosci 22:4015-4024, 2002
PubMed
13) Miura Y, Koyanagi Y, Mizusawa H:TNF-related apoptosis-inducing ligand (TRAIL) induces neuronal apoptosis in HIV-encephalopathy. J Med Dent Sci 50:17-25, 2003
PubMed
14) Xing HQ, Moritoyo T, Mori K, et al:Simian immunodeficiency virus encephalitis in the white matter and degeneration of the cerebral cortex occur independently in simian immunodeficiency virus-infected monkey. J Neurovirol 9:508-518, 2003
PubMed
P.258 掲載の参考文献
1) Prusiner SB, Peters P, Kaneko K, et al:Cell Biology of Prions. Cold Spring Harbor, New York, 1999
 
2) Bolton DC, McKinley M P, Prusiner SB:Identification of a protein that purifies with the scrapie prion. Science, 218:1309-1310, 1982
PubMed
3) Prusiner SB:Molecular biology of prion diseases. Science, 252:1515-1522, 1991
PubMed
4) Kaneko K, Zulianello L, Scott M, et al:Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci USA, 94:10069-10074, 1997
PubMed
5) Bueler H, Aguzzi A, Sailer A, et al:Mice devoid of PrP are resistant to scrapie. Cell, 73:1339-1347, 1993
PubMed
6) Hsiao K K, Scott M, Foster D, et al:Spontaneous neurodegeneration in transgenic mice with mutant prion protein. Science, 250:1587-1590, 1990
 
7) Kaneko K, Ball H L, Wille H, et al:A Synthetic Peptide Initiates Gerstmann-Straussler-Scheinker (GSS) Disease in Transgenic Mice. Running title:A peptide causes Gerstmann-Straussler-Scheinker disease. J Mol Biol, 295:997-1007, 2000
 
8) Peretz D, Williamson R A, Kaneko K, et al:Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature, 412:739-743, 2001
PubMed
9) Bueler H, Fischer M, Lang Y, et al:Norinal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature, 356:577-582, 1992
PubMed
10) Shibuya S, Higuchi J, Shin R W, et al:Protective prion protein polymorphisms against sporadic Creutzfeldt-Jakob disease [letter]. Lancet, 351:419, 1998
PubMed
11) Westaway D, Zuliani V, Cooper C M, et al:Homozygosity for prion protein alleles encoding glutamine-171 renders sheep susceptible to natural scrapie. Genes Dev, 8:959-969, 1994
PubMed
12) Perrier V, Kaneko K, Safar J, et al:Dominant-negative inhibition of prion replication in transgenic mice. Proc Natl Acad Sci U S A, 99:13079-13084, 2002
PubMed
13) Kishida H, Sakasegawa Y, Watanabe K, et al:Non-glycosylphosphatidylinositol (GPI)-anchored recombinant prion protein with dominant-negative mutation inhibits PrPsc replication in vitro. Amyloid, 11:14-20, 2004
PubMed
14) Hachiya N S, Sakasegawa Y, Jozuka A, et al:Interaction of d-lactate dehydrogenase protein 2 (Dld2p) with F-actin:implication for an alternative function of Dld2p. Biochem Biophys Res Commun, 319:78-82, 2004
PubMed
15) Hachiya N S, Sakasegawa Y, S H, et al:Oligomeric Aip2p/Dld2p forms a novel grapple-like structure and has an ATP-dependent F-actin conformation modifying activity in vitro. Biochem Biophys Res Commun, in press, 2004
 
16) Doh-Ura K, Iwaki T, Caughey B:Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol, 74:4894-4897, 2000
PubMed
17) Korth C, May B C H, Cohen F E, et al:Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease:PNAS, 98:9836-9841, 2001
 

第11章 画像診断学の進歩

P.264 掲載の参考文献
1) 興梠征典, 重松良典, 高橋睦正:頭部・頸部のMRA. 臨床画像 14:924-933, 1998
 
2) Arimura H, Li Q, Korogi Y, et al:Automated computerized scheme for detection of unruptured intracranial aneurysms in three-dimensional MRA. Academic Radiology 11:2004 (in press)
 
3) Farb RI, McGregor C, Kim JK, et al:Intracranial Arteriovenous Malformations:Real-Time Auto-triggered Elliptic Centric-ordered 3D Gadolinium-enhanced MR Angiography-lnitial Assessment. Radiology 220:244-251, 2001
PubMed
4) Tsuchiya K, Katase S, Yoshino A, et al:MR Digital Subtraction Angiography of Cerebral Arteriovenous Malformations. American Journal of Neuroradiology 21:707-711, 2000
PubMed
5) Golay X, Brown SJ, Itoh R:Time-Resolved Contrast-Enhanced Carotid MR Angiography Using Sensitivity Encoding (SENSE). American Journal of Neuroradiology 22:1615-1619, 2001
PubMed
6) Liang L, Korogi Y, Sugahara T, et al:Evaluation of the intracranial dural sinuses with a 3D contrast-enhanced MP-RAGE sequence:prospective comparison with 2D-TOF MR venography and digital subtraction angiography. AJNR 22:481-491, 2001
PubMed
7) Korogi Y, et al:Intracranial aneulysms;detection with three-dimensional CT angiography with volume rendering-comparison with conventional angiographic and surgical findings. Radiology 208:423-230, 1998
 
8) Sugahara T, Korogi Y, Nakashima K, et al:Comparison of 2D and 3D digital subtraction angiography in evaluation of intracranial aneurysms. AJNR Am J Neuroradiol 23:1545-1552, 2002
PubMed
9) Hirai T, Korogi Y, Sugkmohara K, et al:Clinical usefulness of unsubtracted 3D digital angiography compared with rotational digital angiography in the pretreatment evaluation of intracranial aneurysms. AJNR Am J Neuroradiol 24:1067-1074, 2003
 
10) Chu B, Kampschulte A, Ferguson MS, et al:Hemorrhage in the Atherosclerotic Carotid Plaque:A High-Resolution MRI Study. Stroke 35:1079-1084, 2004
PubMed
P.268 掲載の参考文献
1) Stehling MK, Turner R, Mansfield P:Echo-planar imaging:magnetic resonance imaging in a fraction of second. Science 254:43-50, 1991
 
2) Edelman RR, Wielopolski P, Schmitt F:Echo-planar MR imaging. Radiology 192:600-612, 1994
 
3) Elster AD:Questions and answers in Magnetic resonance imaging. Mosby, p231, 1994
 
4) Le Bihan D:Diffusion and perfusion magnetic resonance imaging. Raven Press, p9, 1995
 
5) Burdette JH, Elster AD, Ricci PE:Acute cerebral infarction:quantification of spin-density and T2 shine-through phenomena on diffusion-weighted MR images. Radiology 212:333-339, 1999
PubMed
6) Abe O, Okubo T, Hayashi N, et al:Temporal changes of the apparent diffusion coefficients of water and metabolites in rats with hemispheric infarction:experimental study of transhemispheric diaschisis in the contralateral hemisphere at 7 tesla. Journal of Cerebral Blood Flow & Metabolism 20:726-735, 2000
PubMed
7) Roychowdhury S, Maldjian JA, Grossman RI:Multiple sclerosis:comparison of trace diffusion coefficients with MR enhancement pattern of lesions. AJNR 21:869-874, 2000
PubMed
8) Schocke MF, Seppi K, Esterhammer R, et al:Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 58:575-580, 2002
PubMed
9) Ellis CM, Simmons A, Jones DK, et al:Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology. 53:1051-1058, 1999
PubMed
10) Tien RD, Felsberg GJ, Friedman H, et al:MR imaging of high-grade cerebral gliomas:value of diffusion-weighted echo planar pulse sequences. AJR 162:671-677, 1994
 
11) Nakata T, Matsuzawa H, Kwee IL.:Magnetic resonance axonography of the rat spinal cord. Neuroreport 5:2053-2056, 1994
 
12) Ford JC, Hackney DB, Alsop DC, et al:MRI characterization of diffusion coefficients in a rat spinal cord injury model. Magn Reson Med 31:488-494, 1994
 
13) Clark CA, Barker GJ, Tofts PS, et al:Magnetic resonance diffusion imaging of the human cervical spinal cord in vivo. Magn Reson Med 41:1269-1273, 1999
PubMed
14) Wheeler-Kingshott CA, Hickman SJ, Parker GJ, et al:Investigating cervical spinal cord structure using axial diffusion tensor imaging. Neuroimage 16:93-102, 2002
PubMed
15) Takahashi M, Hackney DB, Zhang G, et al:Magnetic resonance microimaging of intraaxonal water diffusion in live excised lamprey spinal cord. Proceedings of the National Academy of Sciences of the United States of America 99:16192-16196, 2002
PubMed
P.274 掲載の参考文献
1) 中田 力:磁気共鳴軸索画像, 日独医報 42:255-263, 1997
 
2) Basser PJ, Mattiello J, et al:MR diffusion tensor spectroscopy and imaging. Biophys J 66:259-267, 1994
PubMed
3) 阿部 修, 青木茂樹編:これでわかる拡散MRI,. 秀潤社, 東京, 2002
 
4) Mori S, Crain BJ, et al:Three dimensional tracking of axonal projections in the brain by magnetic resonance imaging. Ann Neurol 45:265-269, 1999
PubMed
5) Masutani Y, Aoki S, Abe O, et al:MR Diffusion Tensor Imaging:Recent Advance and New Techniques for Diffusion Tensor Visualization. Eur J Radiol 46:53-66, 2003
PubMed
6) Le Bihan D, van Zijl P. From the diffusion coefficient to the diffusion tensor. NMR Biomed 15:431-434, 2002
 
7) Abe O, Aoki S, Hayashi N, et al:Normal aging in the central nervous system:quantitative MR diffusion-tensor analysis. Neurobiology of aging 23:433-441, 2002
PubMed
8) Aoki S, Iwata N, Masutani Y, et al:Quantitative evaluation of the pyramidal tract segmented by diffusion tensor tractography:feasibility study of the patients with amyotrophic lateral sclerosis. Radiation Medicine (in press)
 
9) Yoshikawa K. Nakata Y. Yamada K, et al:Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. Journal of Neurology, Neurosurgery&Psychiatry 75:481-484, 2004
PubMed
10) Aoki, S. Masutani, Y. Iwata, N, et al:Segmentation and quantitative analysis of the white matter tracts by diffusion tensor imaging/tractography, ASNR, Seattle, 2004
 
11) Kunimatsu A, Aoki S, Masutani Y, Abe O, Mori H, Ohtomo K. Three-Dimensional White Matter Tractography by Diffusion Tensor MR Imaging in the Evaluation of Ischaemic Stroke Involving the Corticospinal Tract. Neuroradiology 45:532-535, 2003
 
12) Yamada K. Mori S. Nakamura H, et al:Fiber-tracking method reveals sensorimotor pathway involvement in stroke patients. Stroke 34:E159-162, 2003
PubMed
P.280 掲載の参考文献
1) Moller-Hartmann W, Hemminghaus S, Krings T, et al:Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 44:371-381, 2002
 
2) Hetherington HP, Kim JH, Pan JW, et al:1H and 31P Spectroscopic Imaging of Epilepsy:Spectroscopic and Histologic Correlations. Epilepsia 45 (suppl 4):17-23, 2004
 
3) 石井賢二:脳疾患測定法と正常画像, 臨床医のためのクリニカルPET, 先端医療技術研究所, 東京, p113-121, 2001
 
4) 井形昭弘, 朝倉哲彦, 藤元登四郎:脳神経疾患のMRS, 先端医療技術研究所, 東京, 1997
 
5) Huang W, Alexander GE, Chang L, et al:Brain metabolite concentration and dementia severity in Alzheimer:s disease. Neurology 57:626-632, 2001
PubMed
6) Lu D, Margouleff C, Rubin E, et al:Temporal Lobe Epilepsy:Correlation of Proton Magnetic Resonance Spectroscopy and 18F-Fluorodeoxyglucose Positron Emission Tomography. MRM 37:18-23, 1997
PubMed
7) Fulham MJ, Dietz MJ, Duyn JH, et al:Transsynaptic Reduction in N-Acetyl-Aspartate in Cerebellar Diaschisis:A Proton MR Spectroscopic Imaging Study. J Comput Assist Tomogr 18:697-704, 1994
 
8) 中村克巳, 藤元登四郎, 松本哲郎:MRS, 機能的脳神経外科の最先端, 先端医療技術研究所, 東京, p310-317, 2002
 
9) 内田佳孝, 伊東久夫, 飯森隆志ほか:統計学的画像診断 (3D-SSP).日本放射線技術学会誌 58:1563-1572, 2002
 
10) 石井-成:脳疾患, アルツハイマー病と変性性痴呆, 臨床医のためのクリニカルPET, 先端医療技術研究所, 東京, p131-137, 2001
 
11) 井上輝彦, 藤元登四郎, 三山吉夫ほか:健忘症候群 (早期アルツハイマー型痴呆の疑い) の一症例のPETによる長期的検討, クリニカルPETの最前線, 先端医療技術研究所, 東京, p174-176, 2004
 
12) Dixon RM, Bradley KM, Budge MM, et al:Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocanipus in Alzheimer's disease. Brain 125:2332-2341, 2002
PubMed
13) Jessen F, Block W, Traber F, et al:Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 57:930-932, 2001
 
14) 百瀬敏光:てんかん:クリニカルPETの最前線, 先端医療技術研究所, 東京, p182-185, 2004
 
15) Park S-W, Chang K-H, Kim H-D, et al:Lateralizing Ability of Single-voxel Proton MRS spectroscopy in Hippocampal Sclerosis:Comparison with MR Imaging and Positron Emission Tomography. Am J Neuroradiol 22:625-631, 2001
PubMed
16) 中村克巳, 藤元登四郎:MRS, 脳神経外科の最先端QOLの向上のために, 先端医療技術研究所, 東京, p208-217, 1999
 
17) 川野弘人, 中村克巳, 西井龍一ほか:腫瘍 メチオニンによる脳腫瘍診断, クリニカルPETの最前線, 先端医療技術研究所, 東京, p69-75, 2004
 
18) 中村克巳, 藤元登四郎:MRS, 脳腫瘍の最新医療, 先端医療技術研究所, 東京, p326-332, 2003
 
19) Cho Y-D, Choi G-H, Lee S-P, et al:1H-MRS metabolic patterns for distinguishing between meningiomas and other brain tumors. Magnetic Resonance Imaging 21:663-672, 2003
PubMed
20) Baxter LR Jr, Phelps ME, Mazziotta JC, et al:Cerebral Metabolic Rates for Glucose in Mood Disorders. Arch Gen Psychiatry 42:441-447, 1985
PubMed
21) Baxter LR Jr, Schwartz JM, Phelps ME, et al:Reduction of Prefrontal Cortex Glucose Metabolism Common to Three Types of Depression. Arch Gen Psychiatry 46:243-250, 1989
PubMed
22) Dolan RJ, Bench CJ, Liddle PF, et al:Dorsolateral prefrontal cortex dysfunction in the major psychoses;symptom or disease specificity?. Journal of Neurology, Neurosurgery, and Psychiatry 56:1290-1294, 1993
PubMed
23) Biver F, Goldman S, Delvenne V, et al:Forntal and Parietal Metabolic Disturbances in Unipolar Depression. BIOL PSYCHIATRY 36:381-388, 1994
 
24) 藤元登四郎, 竹内康二, 遠藤雄三ほか:気分障害, クリニカルPETの最前線, 先端医療技術研究所, 東京, p186-193, 2004
 
25) Drevets WC, Price JL, Simpson JR Jr, et al:Subgenual prefrontal cortex abnormalities in mood disorders. NATURE 386:824-827, 1997
PubMed
26) Mayberg HS, Brannan SK, Mahurin RK, et al:Cingulate function in depression:a potential predictor of treatment response. Clinical Neuroscinence and Neuropathology 8:1057-1061, 1997
 
P.286 掲載の参考文献
1) Baule GM, McFee R:Detection of the magnetic field of the heart. Am Heart J 66:96-97, 1963
 
2) Cohen D:Magnetoencephalography:Detection of the brain's electrical activity with a superconducting magnetometer. Science 175:664-666, 1972
 
3) Brenner D, Lipton J, Kaufman L, et al:Somatically evoked magnetic fields of the human brain. Science 199:81-83, 1978
PubMed
4) Tuomisto T, Hari R, Katila T, et al:Studies of auditory evoked magnetic and electric responses:Modality specificity and modeling. Nuovo Cimento D 2:471-483, 1983
 
5) Oe H, Kandori A, Murakami M, et al:Cortical functional abnonmality assessed by auditory-evoked magnetic fields and therapeutic approach in patients with chronic dizziness. Brain Res 957:373-380, 2002
PubMed
6) Kandori A, Oe H, Miyashita K, et al:Visualisation method of spatial interictal discharges in temporal epilepsy patients using magneto-encephalogram. Med Biol Eng Comput 40:327-331, 2002
PubMed
7) Robinson SE, Vrba J:Functional neuroimaging by synthetic aperture magnetometry (SAM) . in Recent Advances in Biomagnetism. Yoshimoto T, Kotani M, Kuriki S, et al (ed):Tohoku University Press, Sendai, p302-305, 1999
 
8) Lin YY, Shih YH, Hsieh JC, et al:Magnetoencephalographic yield of interictal spikes in temporal lobe epilepsy, Comparison with scalp EEG recordings. Neuroimage 19:1115-1126, 2003
 
9) Kamada K, Saguer M, Mollwe M, et al:Functional and metabolic analysis of cerebral ischemia using magnetoencephalography and proton magnetic resonance spectroscopy. Ann Neurol 42:554-563, 1997
 
10) Butz M, Gross J, Timmermann L, et al:Perilesional pathological oscillatory activity in the magnetoencephalogram of patients with cortical brain lesions. Neurosci Lett 355:93-96, 2004
PubMed
11) Vieth J, Grummich P, Sack G, et al:Three dimensional localization of the pathological area in cerebro-vascular accidents with multichannel magnetoencephalography. Biomed Tech (Berl) 35 (Suppl 2):238-239, 1990
 
12) Frernandez A, Maestu F, Amo C, et al:Focal temporoparietal slow activity in Alzheimer's disease revealed by magnetoencephalography. Biol Psychiatry 52:764-770, 2002
PubMed
13) Wienbruch C, Moratti S, Elbert T, et al:Source distribution of neuromagnetic slow wave activity in schizophrenic and depressive patients. Clin Neurophysiol 114:2052-2060, 2003
PubMed
14) Penfield W, Boldrey E:Somatic motor and sensory representation in the cerebral cortex of man as studied by electrical stimulation. Brain 60:389-443, 1937
 
15) Hari R, Reinikainen K, Kaukoranta E, et al:Somatosensory evoked cerebral magnetic fields from S1 and S2 in man. Electroenceph Clin Neurophysiol 57:254-263, 1984
 
16) Yamasaki H, Kakigi R, Naka D:Effects of distraction on pain perception:Magneto-and electro-encephalographic studies. Brain Res Cogn Brain Res 8:73-76, 1999
PubMed
17) Nakasato N, Seki K, Fujita S, et al:Cortical mapping using an MR-linked whole head MEG system and presurgical decision making. Electroenceph Clin Neurophysiol 47 (Suppl):333-341, 1996
 
18) Iwasaki M, Nakasato N, Kanno A, et al:Somatosensory evoked fields in patients with comatose survivors after sever head injury. Clin Neurophysiol 112:204-210, 2001
 
19) Kannno A, Nakasato N, Fujita S, et al:Right hemispheric dominance in the auditory evoked magneticfields for pure-tone stimuli. Electroenceph Clin Neurophysiol 47 (Suppl):129-132, 1996
 
20) Nakasato N, Kumabe T, Kanno A, et al:Neuromagnetic evaluation of cortical auditory function in patients with temporal lobe tumors. J Neurosurg 86:610-618, 1997
PubMed
21) Pantev C, Lutkenhoner B, Hoke M, et al:Comparison between simultaneously record auditory-evoked magnetic fields and potentials elicited by ipsilateral, contralateral and binaural tone burst stimulation. Auditory 25:54-61, 1986
PubMed
22) Oe H, Kandori A, Yamada N, et al:Interhemispheric connection of auditory neural pathways assessed by auditory evoked magnetic fields in patients with fronto-temporal lobe infarction. Neurosci Res 44:483-488, 2002
PubMed
23) Naritomi H, Oe H, Kandori A, et al:Interhemispheric neural conduction time estimated by auditory-evoked magnetic fields is prolonged correlating with the degree of cognitive dysfunction in elderly subjects with unstable gait. J Cereb Blood Flow&Met 23 (Suppl 1):597, 2003
 
24) Oe H, Kandori A, Miyashita T, et al:Prolonged interhemispheric neural conduction time evaluated by auditory-evoked magnetic signal and cognitive deterioration in elderly subjects with unstable gait and dizzy sensation. Inter Cong Seri 1270C:177-180, 2004
 
25) Pekkonen E, Huotilainen M, Virtanen J, et al:Alzheimer's disease affects parallel processing between the auditory cortices. Neuroreport 7:1365-1368, 1996
PubMed
26) Shigeto H, Tobimatsu S, Yamamoto T, et al:Visual evoked cortical magnetic responses to checkerboard pattern reversal stimulation:a study on the neural generators of N75, P100 and N145. J Neurol Sci 156:186-194, 1998
 
27) Hall SD, Barnes GR, Hillebrand A, et al:Spatio-temporal imaging of cortical desynchrnoization in migraine visual aura:a magnetoencephalography case study. Headache 44:204-208, 2004
PubMed
28) Cheyne D, Weinberg H, Gaetz W, et al:Motor cortex activity and predicting side of movement:Neural network and dipole analysis of premovement magnetic fields, Neurosci Lett 188:81-84, 1995
PubMed
29) Kato A, Yoshimine T, Hirata M, et al:Event-related desynchrnoization analyzed with SAM-SPM for functional brain mapping. Yoshimoto T et al (ed):Recent Advances in Biomagnetism. Tohoku University Press, p244-247, 1999
 
30) 成冨博章 平成16年度循環器病研究委託研究班15公-3:脳磁図 (MEG) を用いた脳虚血による局所性機能異常の非侵襲的診断法に関する研究.
 

第12章 神経疾患における新しい動態計測

P.293 掲載の参考文献
1) Holmes G:The symptoms of acute cerebellar injuries due to gunshot injuries. Brain 40:461-535, 1917
 
2) Agostino R, Berardelli A, Curra A, et al:Clinical impairment of sequential finger movements in Parkinson's disease. Mov Disord 13:418-421, 1998
PubMed
3) 中村隆一:小脳疾患, ・パーキンソニズムの反復交互障害. 神経進歩 19:719-724, 1975
 
4) Shimoyama I, Hinokuma K, Ninchoji T, et al:Microcomputer analysis of finger tapping as a measure of cerebellar dysfunction. Neurol Med Chir 23:437-440, 1983
PubMed
5) Nagasaki H, Itou H, Maruyama H, et al:Characteristic difficulty in rhythmic movement with aging and its relation to Parkinson's disease. Exp Aging Res 14:171-176, 1988
 
6) Freeman JS, Cody FW, Schady W:The influence of external timing cues upon the rhythm of voluntary movements in Parkinson's disease. J Neurol Neurosurg Psychiatry 56:1078-1084, 1993
PubMed
7) Giovannoni G, van Schalkwyk J, Fritz VU, et al:Bradykinesia akinesia incoordination test (BRAIN TEST):an objective computerized assessment of upper limb motor function. J Neurol Neurosurg Psychiatry 67:624-629, 1999
PubMed
8) Bronte-Stewart HM, Ding L, Alexander C, et al:Quantitative digitography (QDG):a sensitive measure of digital motor control in idiopathic Parkinson's disease. Mov Disord 15:36-47, 2000
PubMed
9) Frischer M:Voluntary vs autonomous control of repetitive finger tapping in a patient with Parkinson's disease. Neuropsychologia 27:1261-1266, 1989
 
10) Konczak J, Ackermann H, Hertrich I, et al:Control of repetitive lip and finger movements in Parkinson's disease:influence of external timing signals and simultaneous execution on motor performance. Mov Disord 12:665-676, 1997
PubMed
11) Agostino R, Curra A, Giovannelli M, et al:Impairment of Individual Finger Movements in Parkinson:s Disease. Mov Disord 18:515-523, 2003
 
12) Kandori A, Yokoe M, Sakoda S, et al:Quantitative magnetic detection of finger movements in patients with Parkinson's disease. Neurosci Res 49:253-260, 2004
PubMed
13) Goetz CG, Stebbins GT, Chumura TA, et al:Teaching tape for the motor section of the Unified Parkinson's disease rating scale. Mov Disord 10:263-266, 1995
 
14) 柳沢信夫:パーキンソン病の運動障害機序. 脳神経 41:647-658, 1989
 
P.299 掲載の参考文献
1) Mussa-lvaldi F.A, Hogan N, Bizzi E:Neural, mechanical, and geometric factors subserving arm posture in humans. Journal of Neuroscience 5:2732-2743, 1985
 
2) Tsuji T, Morasso PG, Goto K, et al:Human hand impedance characteristics during maintained posture. Biological Cybernetics 72:475-485, 1995
PubMed
3) 辻 敏夫, 森谷正三, 金子 真ほか:等尺性筋収縮における人間の手先インピーダンスの解析. 計測自動制御学会論文集 32:271-280, 1996
 
4) Sakane A, Tsuji T, Saeki N, et al:Discrimination of Vascular Conditions Using a Probabilistic Neural Network, Journal of Robotics and Mechatronics 16:138-145, 2004
 
5) 青柳卓雄, 鵜川貞二:パルスオキシメータの原理と構造. Clinical Engineering 7:102-110, 1996
 
6) 加賀谷淳子, 中村好男編著:運動と循環-研究の現状と課題, ナップ, 東京, p304, 2001
 
7) Bayliss WM:On the local reactions of the arterial wall to changes of internal pressure. J Physiol 28:220-231, 1902
PubMed
8) Drott C, Gothberg G, Claes G:Endoscopic transthoracic sympathectomy:an efficient and safe method for the treatment of hyperhidrosis. Joumal of the American Academy of Dermatology 33:78-81, 1995
 
9) Saeki N, Kawamoto M, Yuge O:Quantitative view of peripheral circulation. Critical Care Medicine 28 (suppl):A62, 2000
 
10) Tsuji T, Fukuda O, Ichinobe H, et al:A Log-Linearized Gassian Mixture Network and lts Application to EEG Pattern Classification. IEEE Trans. Syst., Man, Cybern-Part C, Appl. and Rev 29:60-72, 1999
 
11) Rady MY, Nightingale P, Little RA, et al:Shock index:a re-evaluation in acute circulatory failure Resuscitation 23:227-234, 1992
PubMed
P.304 掲載の参考文献
1) Abe K, Asai Y, Matsuo Y, et al:Classifying lower limb dynamics in Parkinson's disease. Brain Research Bulletin 61:219-226, 2003
PubMed
2) Matsuo Y, Asai Y, Nomura T, et al:Intralimb incoordination in patients With ataxia. Neuro Report 14 (16):2057-2059, 2004
 
3) Asai Y, Nomura T, Sato S, et al:A coupled oscillator model of disordered interlimb coordination in patients with Parkinson's disease. Biological Cybernetics 88:152-162, 2003
 
4) Asai Y, Nomura T, Abe K, et al:Classification of dynamics of a model of motor coordination and comparison with Parkinson's disease data. Biosystems 71:11-21, 2003
 
5) Schillings AM, van Wezel BM, Mulder T, et al:Muscular responses and movement strategies during stumbling over obstacles. J Neurophysiol 83 (4):2093-102, 2000
PubMed
6) 小林誠, 野村泰伸, 佐藤俊輔:ヒトの二足歩行運動のインパルス状外乱に対する応答とその中枢神経機構に基づく解釈. 医用電子と生体工学 38 (1):20-32, 2000
 
7) Yamasaki T, Nomura T, Sato S:Possible functional roles of phase resetting during walking. Biological Cybernetics 88:468-496, 2003
PubMed
8) Yamasaki T, Nomura T, Sato S:Phase reset and dynamic stability during human gait. Biosystems 71:221-232, 2003
PubMed
9) Belair J, Glass L, Van der Heiden U, et al:Dynamical disease:Identification, temporal aspects and treatment strategies of human illness. Chaos 5:1-7, 1995
 

第13章 各種製品の臨床評価

P.309 掲載の参考文献
1) Savi P, Combalbert. C, Gaichi MC,, et al:The antiaggregating activity of clopidogrel is due to a metabolic activation by cytochrome P450-1-A. Thromb Haemost 72:313-317, 1994
 
2) Savi P, Pereillo M, Uzabiaga J, et al:Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891-896, 2000
 
3) Yoneda K, Iwamura R, Kishi H:Identification of the active metabolite of ticlopidine from rat in vitro metabolite. Br J Phamlacol 142:551-557, 2004
PubMed
4) Savi P, Labouret N, Delesque F, et al:P2Y12, a new platelet ADP receptor, target of clopidogrel Biochem Biophys Res Commun 283:379-383, 2001
 
5) Pianet I, Merle M, and Labouesse J. ADP and, indirectly, ATP are potent inhibitors of cAMP production in intact isoproterenol-stimulated C6 glioma cells. Biochem Biophys Res Commun 163, 1150-1157, 1989
PubMed
6) Simon J, Filippov AK, Goransson S et al:Characterization and channel coupling of the P2Y (12) nucleotide receptor of brain capillary endothelial cells. J Biol Chem 277:31390-31400, 2002
PubMed
7) Wihlborg AK, Wang L, Braun OO, et al:ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 24:1-7, 2004
PubMed
8) Holmsen H:Significance of testing platelet functions in Vitro. Eur J Clin Invest 24 (suppl 1):3, 1994
 
9) Moake JL, Turner NA, Stathopoulos NA, et al:Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 71:1366-1374, 1988
PubMed
10) Uchiyama S, Yamazaki M, Maruyama. Shear-induced platelet aggregation in cerebral ischemia. Stroke 25:1547-1551, 1994
PubMed
11) Orford JL, Kinlay S, Adams MR, et al:Clopidogrel inhibits shear-induced platelet function. Platelets. 13:187-189, 2002
PubMed
12) Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 76:939-943, 1996
PubMed
13) 池田康夫, 内山真一郎, 山口武典ほか:硫酸クロピドグレルの血小板凝集抑制作用-用量比較臨床薬理試験-. 脳卒中 24:381-392, 2002
 
14) CAPRIE steering committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) . Lancet 348:1329-1339, 1996
 
15) Ringleb PA, Bhatt DL, Hirsch AT, et al:Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 35:528-532, 2004.
PubMed
16) Yusuf S, Zhao F, Mehta SR, Chrolavicius S et la. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502, 2001
 
17) Diener HC, Bogousslavsky J, Brass. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH):randomised, double-blind, placebo-controlled trial. Lancet 364:331-337, 2004
PubMed
18) Peters RJ, Mehta SR, Fox KA, et al:Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes:observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108:1682-1687, 2003
PubMed
19) Mehta SR, Yusuf S, Peters RJ, et al:Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study. Lancet 358:527-533, 2001
PubMed
20) Ringleb PA, Schellinger PD and Schwark C. Clopidogrel in the management of cerebrovascular events. Int J Clin Pract 58:402-410, 2004
PubMed
21) Zakarija A, Bandarenko N, Pandey DK, et al:An update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the food and drug administration. Stroke 35:533-538, 2004
PubMed
22) クロピドグレル添付文書 (米国)
 
23) Furlan M, Robles R, Galbusera M, et al:von Willebrand Factor-Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic?Uremic Syndrome. N Engl J Med 339:1578-1584, 1998
PubMed
24) Tsai HM, Rice L, Sarode R. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 132:794-799, 2000
PubMed
25) Sugidachi A, Asai F, Yoneda K Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747. Br. J. Pharmacol 132:47-54, 2001
PubMed
26) Lau WC, Waskell LA, Watkins PB:Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation:a new drug-drug interaction. Circulation 107:32-37, 2003
PubMed
27) Wienbergen H, Gitt AK, Schiele R, et al:Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 92:285-288, 2003
PubMed
28) Saw J, Steinhubl SR, Berger PB, et al:Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108:921-924, 2003
PubMed
29) Muller I, Besta F, Schulz C. Effects of statins on platelet inhibition by a high loading dose of clopidogrel Circulation 108:2195-2197, 2003
PubMed
30) Mitsios JV, Papathanasiou AI, Rodis FI, et al:Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 109:1335-1338, 2004
 
31) Peeters PA, Crijns HJ, Tamminga WJ, et al:Clopidogrel, a novel antiplatelet agent, and digoxin:absence of pharmacodynamic and pharmacokinetic interaction. Semin Thromb Hemost 25 (suppl 2):51-54, 1999
 
32) Caplain H, Thehault JJ and Necciari J:Clopidogrel does not affect the pharmacokinetics of theophylline. Semin Thromb Hemost 25 (suppl 2):65-68, 1999
 
33) Forbes CD, Lowe GD, MacLaren M:Clopidogrel compatibility with concomitant cardiac co-medications:a study of its interactions with a beta-blocker and a calcium uptake antagonist. Semin Thromb Hemost 25 (suppl 2):55-60, 1999
 
P.313 掲載の参考文献
1) Nakashima I, Fujinoki M, Fujihara K, et al:Detection of biomarkers for multiple sclerosis in cerebrospinal fluid using SELDI-TOF Protein Chip (TM) technology. Neurology 62 (7):A39-A39, 2004
 
2) Davies H, Lomas L, Austen B:Biotechniques 27:1258-1262, 1999
PubMed
3) 丹羽利充編:ポストゲノム・マススペクトロメトリー生化学のための生体高分子解析化学フロンティア, 化学同人, 京都) , 2003
 

技術資料編

P.320 掲載の参考文献
1) 社団法人日本アイソトープ協会医学・薬学部会放射性医薬品安全性専門委員会:放射性医薬品副作用事例調査報告第25報 (平成14年度第28回調査). 核医学 41:33-46, 2004
 
2) Lever SZ, Bums HD, Kervitsky TM, et al:Design, preparation, and biodistribution of a technetium-99m triaminedithiol complex to assess regional cerebral blood flow. J Nucl Med 26:1287-1294, 1985
 
3) Kung HF, Molnar M, Billings J, et al:Synthesis and biodistribution of neutral lipid-soluble Tc-99m complexes that cross the blood-brain barrier. J Nucl Med 25:326-332, 1984
PubMed
4) Cheesman EH, et al:J Nucl Med 29:788, 1988
 
5) Orlandi C, Crane PD, Platts SH, et al:Regional cerebral blood flow and distribution of [99mTc]ethyl cysteinate dimer in nonhuman primates. Stroke 21:1059-1063, 1990
PubMed
6) Walovitch RC, Hill TC, Garrity ST, et al:Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, Part 1:Pharmacology of technetium-99m ECD in nonhuman primates. J Nucl Med 30:1892-1901, 1989
 
7) 久保敦司, 中村佳代子, 塚谷泰司ほか:99mTc-ECD の第I相臨床試験. 核医学 29:1019-1027, 1992
Medical*Online
8) 米倉義晴, 佐々木康人, 久保敦司ほか:局所脳血流イメージング剤 99mTc-ECD の臨床的有用性の検討-他施設による第III相臨床試験-. 核医学 30:397-410, 1993
 
9) 藤本茂, 豊田一則, 井上亨ほか:頸動脈内膜剥離術後の過還流症候群における造影径頭蓋カラードプラの有用性. 脳神経外科ジャーナル 13:482-489, 2004
 
10) Matsuda H, Tsuj i S, Shuke N, et al:A quantitative approach to technetium-99m hexamethylpropylene amine oxime. Eur J Nucl Med 19:195-200, 1992
 
11) Matsuda H, Yagishita A, Tsuji S, et al:A quantitative approach to technetium-99m ethyl cysteinate dimer:a comparison with technetium-99m hexamethylpropylene amine oxime. Eur J Nucl Med 22:633-637, 1995
PubMed
12) Latchaw RE, Yonas H, Hunter GJ, et al:Guidelines and recommendations for perfusion imaging in cerebral ischemia:A scientific statement for healthcare professionals by the writing group on perfusion imaging, from the Council on Cardiovascular Radiology of the American Heart Association. Stroke 34:1084-1104, 2003
 
13) 西村恒彦監修, 平井俊策, 端 和夫ほか編:治療につながる脳血流SPECT定量, メディカルレビュー社, 大阪, p1-161, 1999
 
14) Matsuda H, Mizumura S, et al:Conversion of brain SPECT images between different collimators and reconstruction processes for analysis using statistical parametric mapping. Nucl Med Commun 25:67-74, 2004
PubMed
15) Kanetaka H, Matsuda H, Asada T, et al:Effects of partial volume correction on discrimination between very early Alzheimer's dementia and controls using brain perfusion SPECT. Eur J Nucl Med Mol Imaging 31:975-980, 2004
PubMed
P.325 掲載の参考文献
1) 久田欣一監修:最新臨床核医学第3版, 金原出版, 東京, p97, 1999
 
P.328 掲載の参考文献
1) 杉原正康ほか:高齢者に投与最適な新規製剤および新規包装容器の作成研究.厚生省厚生科学研究シルバーサイエンス研究報告, 1988
 
2) 藤田けい士ほか:食道癌の治療硫酸ペプロマイシンの経口的投与 (ペプレオゼリー) による治療の試み:診療手帖 93:31-34, 1986
 
3) Imura A:Considerations on pharmaceutical preparations. From the standpoint of physicians. Gerontology. Problems in medication to elderly people. Med Pharm 20 (2):73-75, 1986
 
4) 内田公子ほか:漢方製剤における剤形の検討第1 報:薬局 42 (11):53-59, 1991
 
5) 太田ひさよほか:漢方製剤における剤形の検討第2報. 薬局 43 (2):57-61, 1992
 
6) 加納公子ほか:漢方製剤における剤形の検討第3 報. 薬局 44 (4):43-46, 1993
 
7) 佐々木由美ほか:ペクシーを用いたカリメートゼリーによる高カリウム血症の是正について. 診療と新薬 31 (11):73-76, 1994
 
8) 大樂真健, 富樫美津雄:エアープッシュゼリー製剤の開発と包装設. 包装技術 41:836-841, 2003
 
9) シロスレット内服ゼリー. 医薬品インタビューフォーム
 
10) 坂下裕子ほか:ゼリー製剤の有用性[医薬品の新たな剤形として]. PHARM TECH JAPAN 19 (13):2367-2377, 2003
 
11) シロスレット内服ゼリーの製品パンフレット
 
P.332 掲載の参考文献
1) 鈴木英文:直接変換方式FPD搭載循環器システム DIGITEX Safire. 映像情報722号:174-178, 2004
 
2) 三浦嘉章ほか:直接型FPD (Safire) 搭載デジタル血管造影システムの臨床評価報告. 島津評論 59:141-146, 2002
 
3) 三浦嘉章:回転DSAを含めた新しいFPD搭載装置.画像通信 27:26-31, 2004
 
P.339 掲載の参考文献
1) 齋藤泰男:最新技術報告Next Frontiers 人体の動きをとらえる4D-CTの現状と展望. INNERVISION 17(5) 別冊付録:24-26, 2002
 
2) 片田和廣:32列マルチスライスCTの役割. Multislice CT 2004 BOOK 36(6):57-58, 2004
 
3) 寺田友昭:マルチスライスCTを用いた脳循環動態の評価.メディカルレビュ-90 27 (5):33-39, 2003
 
4) 佐々木真理:マルチスライスCTの現状と将来. Multislice CT 2003 BOOK 35(7)):44-45, 2003
 

書評

最近チェックした商品履歴

Loading...